A Phase II Study of Niraparib and Dostarlimab With Radiation in Patients With Metastatic Pancreatic Cancer
Phase: PHASE2
Conditions: Pancreatic Cancer, Metastatic Pancreatic Cancer
Sponsor: Massachusetts General Hospital

Page 1
DF/HCC Protocol #: 19-538 
TITLE:  A Phase II Study of niraparib and dostarlimab with radiation in patients with metastatic 
pancreatic cancer
Principal Investigator (PI):
Ted Hong, MD
Massachusetts General Hospital
tshong1@mgh.harvard.edu
Other Investigators:
Aparna Parikh, MD, MS
Massachusetts General Hospital
aparna.parikh@mgh.harvard.edu
IND #:  147232
IND Sponsor:  Theodore Hong, MD  
Protocol Type / Version # / Version Date:
Original / Version 2 /    January 21, 2021
NCT04409002

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
2
SCHEMA
Metastatic 
Pancreatic 
Cancer
Cycle 1
Niraparib 
and 
Dostarlimab
Cycle 2
Niraparib
Dostarlimab
Radiation
-
Liver
-
Nodal
-
Lung
-
Soft 
tissue
Cycle 3+
Niraparib
and 
Dostarlimab
until
taken off 
therapy
Biopsy with 
fiducial 
placement
Biopsy
Biopsy
Baseline Scans
Baseline Tissue
Baseline Blood
Baseline Labs

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
3
TABLE OF CONTENTS
SCHEMA.........................................................................................................................................2
1.
OBJECTIVES......................................................................................................................5
1.1
Study Design............................................................................................................5
1.2
Primary Objective....................................................................................................5
1.3
Secondary Objectives...............................................................................................5
1.4
Exploratory Objective..............................................................................................5
2.
BACKGROUND .................................................................................................................5
2.1
Study Disease...........................................................................................................5
2.2
Niraparib ..................................................................................................................6
2.3
Dostarlimab............................................................................................................10
2.4
Radiation Therapy..................................................................................................12
2.5
Rationale ................................................................................................................14
2.6
Correlative Studies Background ............................................................................14
2.7
Patient Reported Outcomes Background...............................................................15
3.
PARTICIPANT SELECTION...........................................................................................16
3.1
Inclusion Criteria ...................................................................................................16
3.2
Exclusion Criteria ..................................................................................................18
3.3
Inclusion of Women and Minorities ......................................................................20
4.
REGISTRATION PROCEDURES ...................................................................................20
4.1
General Guidelines for DF/HCC Institutions ........................................................20
4.2
Registration Process for DF/HCC Institutions.......................................................21
5.
TREATMENT PLAN........................................................................................................21
5.1
Drug Therapy.........................................................................................................21
5.2
Radiation Therapy..................................................................................................22
5.3
Pre-Treatment Evaluations.....................................................................................26
5.4
General Concomitant Medications ........................................................................26
5.5
Supportive Care Guidelines...................................................................................27
5.6
Criteria for Taking a Participant Off Protocol Therapy.........................................29
5.7
Duration of Follow Up...........................................................................................29
5.8
Criteria for Taking a Participant Off Study ...........................................................30
6.
DOSING DELAYS/DOSE MODIFICATIONS ...............................................................30
6.1
Radiation Dose Modifications ...............................................................................30
6.2
Dostarlimab Dose Modifications...........................................................................30
6.3
Niraparib Dose Modifications................................................................................34
7.
EXPECTED TOXICITIES AND TOXICITY REPORTING...........................................38
7.1
Expected Toxicities................................................................................................38
7.2
Adverse Event Characteristics...............................................................................41
7.3
Expedited Adverse Event Reporting......................................................................43

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
4
7.4
Collection and Recording of Adverse Events........................................................44
7.5
Follow-Up of Adverse Events ...............................................................................45
7.6
Reporting to GSK ..................................................................................................45
7.7
Reporting to the Food and Drug Administration (FDA) .......................................46
7.8
Reporting to Hospital Risk Management...............................................................46
7.9
Routine Adverse Event Reporting .........................................................................47
8.
PHARMACEUTICAL INFORMATION..........................................................................47
8.1
Dostarlimab............................................................................................................47
8.2
Niraparib ................................................................................................................48
9.
BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES ........................................49
9.1
Analysis for Repeat RNA Expression, DNA Damage Response, and 
Immune Infiltrates..................................................................................................49
9.2
Functional DNA Damage Response Biomarkers ..................................................51
9.3
Blood-based Correlative Studies............................................................................51
9.4
Patient Reported Outcomes....................................................................................52
10.
STUDY CALENDAR .......................................................................................................52
11.
MEASUREMENT OF EFFECT .......................................................................................55
11.1
Antitumor Effect – Solid Tumors ..........................................................................55
12.
DATA REPORTING / REGULATORY REQUIREMENTS...........................................55
12.1
Data Reporting.......................................................................................................55
12.2
Data Safety Monitoring..........................................................................................56
13.
STATISTICAL CONSIDERATIONS...............................................................................56
13.1
Study Design..........................................................................................................56
13.2
Sample Size, Accrual Rate and Study Duration ....................................................56
13.3
Interim Monitoring Plan ........................................................................................57
13.4
Analysis of Primary Endpoint................................................................................57
13.5
Analysis of Secondary and Exploratory Endpoints ...............................................57
13.6
Reporting and Exclusions ......................................................................................58
14.
PUBLICATION PLAN .....................................................................................................58
REFERENCES ..............................................................................................................................59
APPENDIX A
PERFORMANCE STATUS CRITERIA ..................................................62
APPENDIX B
NIRAPARIB DRUG DIARY....................................................................63

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
5
1. OBJECTIVES
1.1
Study Design
This two-stage single arm phase II trial will evaluate the efficacy of niraparib with dostarlimab 
and radiation therapy in patients with metastatic pancreatic cancer 
1.2
Primary Objective

To estimate the disease control rate of the combination of niraparib and dostarlimab with 
radiation in patients with metastatic pancreatic cancer by RECIST 1.1
1.3
Secondary Objectives

To estimate the disease control rate of the combination of niraparib and dostarlimab with 
radiation in patients with metastatic pancreatic cancer by irRECIST

To estimate progression-free survival in patients with metastatic pancreatic cancer treated 
with niraparib and dostarlimab with radiation

To estimate overall survival in patients with metastatic pancreatic cancer treated with 
niraparib and dostarlimab with radiation

To describe toxicity of niraparib and dostarlimab with radiation in patients with 
metastatic pancreatic cancer
1.4
Exploratory Objective

To explore the potential synergistic effect of anti-PD1 and PARP inhibition with 
radiation using multiplexed immune IF and RNAseq, to assess the change in immune 
microenvironment between pre-treatment, post anti-PDI/PARP and post radiation 
biopsies

To monitor response and define mechanisms of resistance to anti-PD1 and PARP 
inhibition with radiation using serial cfDNA analyses.

Assess the relationship between MSI status and clinical outcomes.

Assess patients’ symptom burden and quality of life by combining objective endpoints 
with subjective patient reported outcomes.  
2. BACKGROUND
2.1
Study Disease
Pancreatic cancer was the third leading cause of death from cancer in the United States in 2017 
(Siegel 2017). The 5-year relative survival rate is a dismal 8% with most patients presenting with 
metastatic disease and treatment options limited to chemotherapy with median OS between 8.5-

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
6
11.1 months with one line of chemotherapy (Conroy 2011, Von Hoff 2013). 
The homologous recombination repair (HRR) pathway is an important pathway in tumor biology 
allowing cancer cells a mechanism to resist damage by treatment modalities such a 
chemotherapy and radiotherapy. PARP enzymes are needed to repair DNA single strand breaks 
and inhibition of PARP enzymes leads to persistence of single strand breaks that will then 
become double stranded breaks, which are more problematic during DNA replication. During the 
process of repair, these breaks may be repaired by functioning HRR pathway proteins. Proteins 
such as BRCA1 and BRCA2 are required for repair of these double stranded DNA breaks 
through the HHR pathway (Curtin, 2012). Tumors with HR deficiency, such as those with 
mutant BRCA1 and BRCA2, have an impaired ability to repair themselves and are susceptible to 
PARP inhibition. PARP helps repair damaged DNA and blocking PARP may prevent cancer 
cells from repairing. Besides inducing cell-intrinsic apoptosis, recent studies have demonstrated 
that PARP inhibitors have immunoregulatory effects in the tumor microenvironment, which may 
enhance the sensitivity to immunotherapy (Huang, 2015). PARP inhibitors have been shown to 
have activity as monotherapy in tumors with existing DNA repair defects such as BRCA1 and 
BRCA2 and in combination therapy with chemotherapy, which induces DNA damage in ovarian 
cancer (Matulonis 2017, 2016). Ionizing radiation is also a known way to induce DNA breaks 
and there is ongoing work suggesting that PARP inhibitors may be used for radio sensitization. 
Though the BRCA genes may be the most well-described genes involved with homologous 
repair, there are several other genes and their associated proteins such as ATM, CHK2, ATR, 
PALB and other Fanconi genes that are involved with DNA damage response and are mutated in 
many cancers and may expand the therapeutic potential for PARP inhibitors. A prospective 
characterization of pancreatic ductal adenocarcinoma (PDAC) patients found germline BRCA 
mutations in nearly 5% of patients; that is consistent with other data (Holter, 2015). In addition 
to germline mutations, there can be somatic mutations in the HRD pathway. A study by Waddell, 
et. al. identified germline and somatic mutations in eight other DNA-damage repair pathways in 
pancreatic cancer. They also demonstrated that patients with these mutations were more likely to 
have unstable patterns of genomic structural variation further suggesting expansion of the patient 
pool (Waddell, 2015). However, independent of HR defects, there is emerging clinical evidence 
that the combination of PARP inhibitors and anti-PD1 therapy may have activity in solid tumors 
with the ability to potentiate neoantigen production as one hypothesis. Inhibiting the DDR 
pathway in combination therapy is being explored in many solid tumors (Brown 2017). Given 
the immunomodulatory and radio-sensitizing effects of PARP inhibitors, we propose a 
combination of niraparib and dostarlimab with radiation. This may induce a synergistic anti-
neoplastic effect, thus providing an opportunity for the expanded use of PARP inhibitors and 
immunothearpy in pancreatic cancers. 
2.2
Niraparib
Niraparib is an orally available, highly selective poly (adenosine diphosphate [ADP]-ribose) 
polymerase (PARP) inhibitor, with activity against PARP-1 and PARP-2 deoxyribonucleic acid 
(DNA)-repair polymerases (Jones 2015). Niraparib is being investigated for the treatment of 
ovarian, breast, and prostate tumors in patients with DNA-repair anomalies. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
7
Phase 1 Study of Niraparib Monotherapy in Advanced Solid Tumors
Clinical activity data for niraparib administered as monotherapy in patients with ovarian cancer 
are available from 1 early-phase clinical study. In Parts A and B of the Phase 1 study PN001 
(ClinicalTrials.gov identifiers: MK-4827-001 and 2008_501), 100 patients with advanced solid 
tumors who had received a median of 3 prior therapies were enrolled; 49 patients had ovarian 
cancer (13 platinum-sensitive, 35 platinum-resistant, and 1 platinum-refractory).11 An additional 
4 patients were enrolled in Part D of the study, which assessed pharmacokinetics only.60 
The most common nonhematological TEAEs were nausea, fatigue, anorexia, constipation, 
vomiting, and insomnia. These TEAEs were mainly mild to moderate in severity, self-limiting, 
and manageable with standard treatments. Hematological toxicity appeared to be dose 
proportional and most frequently arose in the setting of cumulative doses. Anemia was reported 
in 48 (48%) of 100 patients and was Grade ≥3 in 10 (10%) of 100 patients. Thrombocytopenia 
was less common (35 [35%] of 100 patients) and was Grade ≥3 in 15 (15%) of 100 patients. 
Neutropenia was the least commonly reported (24 [24%] of 100 patients), and was Grade 3 in 
4 (4%) of 100 patients at niraparib doses of 300 and 400 mg. In all cases, hematological TEAEs 
were uncomplicated and reversible. Twenty patients required dose reductions (usually by 1 dose 
level) for recurrent anemia or thrombocytopenia. Treatment was discontinued due to AEs in 
7 patients, including the 4 patients who had DLTs during the first cycle and 3 patients who had 
Grade 3 vomiting, Grade 2 prolongation of QT interval, and Grade 3 prolongation of QT 
interval. No treatment-related deaths occurred.
Of the 49 patients, 22 had confirmed BRCA1 or BRCA2 mutation, of whom 20 were 
radiologically assessable. Eight (40%) of these 20 patients achieved a confirmed partial response 
(PR) by Response Evaluation Criteria in Solid Tumors (RECIST) and cancer antigen 125 
(CA-125) Gynecologic Cancer Intergroup criteria at doses ranging from 80 to 400 mg per day. 
Median response duration was 387 days (range: 159 to 518 days). Three (33%) of 9 patients with 
platinum-resistant BRCAmut ovarian cancer had PR by RECIST and CA-125 criteria. In patients 
with platinum-sensitive disease, 5 (50%) of 10 patients (95% CI: 19 to 81) with BRCA1 or 
BRCA2 mutations had RECIST and CA-125 responses.
Phase 3 Study of Niraparib Monotherapy in Platinum-sensitive, Recurrent Ovarian Cancer
In the randomized, double-blind, Phase 3 NOVA trial (Niraparib Maintenance Therapy in 
Platinum-Sensitive, Recurrent Ovarian Cancer), a total of 553 patients were randomized at 
107 centers worldwide. Patients were categorized according to the presence or absence of a 
gBRCAmut (gBRCA cohort and non-gBRCA cohort) within their tumors and the type of 
non-gBRCAmut and were randomly assigned in a 2:1 ratio to receive niraparib (300 mg) or 
placebo once daily (QD). The primary end point was PFS. The study enrolled 203 patients in the 
gBRCAmut cohort and 350 patients in the non-gBRCAmut cohort. Among the 350 patients in the 
non-gBRCAmut cohort, 162 had tumors that were identified as homologous recombination 
deficiency positive (HRDpos), and 134 had tumors that were HRD negative (HRDneg). HRD 
status was not determined for 54 patients.
Demographic and baseline characteristics were well balanced.  Table 1 below shows the results 
for the PFS primary endpoint for each of the 3 primary efficacy populations (ie, gBRCAmut 
cohort, HRDpos cohort, and overall non-gBRCAmut cohort). In addition, median PFS in patients 
with HRDneg tumors was 6.9 months (95% confidence interval [CI]: 5.6, 9.6) in the niraparib 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
8
arm, versus 3.8 months (95% CI: 3.7, 5.6) in the placebo arm, with a HR of 0.58 (95% CI: 0.361, 
0.922) (p = 0.0226).
Table 1: Progression-Free Survival in Ovarian Cancer Patients in NOVA
gBRCAmut Cohort
Non-gBRCAmut Cohort 
(Regardless of HRD 
Status)
HRDpos (Within 
non-gBRCAmut Cohort)
Niraparib 
(n = 138)
Placebo 
(n = 65)
Niraparib 
(n = 234)
Placebo 
(n = 116)
Niraparib 
(n = 106)
Placebo 
(n = 56)
Median PFS 
(95% CI)(i)
21.0
(12.9, NE)
5.5
(3.8, 7.2)
9.3
(7.2, 11.2)
3.9
(3.7, 5.5)
12.9
(8.1, 15.9)
3.8
(3.5, 5.7)
p-value(ii)
< 0.0001
< 0.0001
< 0.0001
HR (niraparib: 
placebo) (95% CI)(iii)
0.27
(0.173, 0.410)
0.45
(0.338, 0.607)
0.38
(0.243, 0.586)
Source: PR-30-5011-C (NOVA main) CSR
Abbreviation: CI = confidence interval; CSR = clinical study report; gBRCAmut = germline BRCA mutation; HR = 
hazard ratio; HRD = homologous recombination deficiency; HRDpos = homologous recombination deficiency 
positive; NE = not evaluated; PFS = progression-free survival.
a PFS is defined as the time in months from the date of randomization to progression or death.
b Based on stratified log-rank test using randomization stratification factors.
c Based on the stratified Cox proportional hazards model using randomization stratification factors.
The primary data to support the safety of treatment with niraparib are derived from the NOVA 
main study in which a total of 546 patients received study treatment.
All 367 patients who received niraparib and 171 (96%) of 179 patients who received placebo 
experienced at least 1 treatment-emergent adverse event (TEAE). The high rate of TEAEs in the 
placebo group indicates the burden of prior chemotherapy and the patient’s underlying ovarian 
cancer. Review of the data across study cohorts for TEAE incidence showed that, in general, the 
results were similar in the gBRCAmut and non-gBRCAmut cohorts. In the overall safety 
population, for the niraparib versus placebo treatment arms, the incidences of Grade 3 or 4 
TEAEs (74% vs. 23%), serious adverse events (SAEs) (30% vs. 15%), TEAEs leading to 
treatment interruption (67% vs. 15%), TEAEs leading to dose reduction (69% vs. 5%), and 
TEAEs leading to treatment discontinuation (15% vs. 2%) were higher for niraparib than for 
placebo. There were no on-treatment deaths reported.
The most commonly observed nonhematologic TEAEs (all grades) observed in niraparib-treated 
compared with placebo-treated patients were nausea (74% vs. 35%), fatigue (46% vs. 32%), 
constipation (40% vs. 20%), and vomiting (34% vs. 16%). The majority of the nonhematological 
TEAEs were mild to moderate in severity. The most commonly observed hematologic TEAEs 
(all grades) of niraparib were anemia (49%), thrombocytopenia (46%), decreased platelet count 
(20%), and neutropenia (18%). Although Grade 3 or 4 hematologic laboratory AEs were 
common at the initiation of study treatment, no severe clinical sequelae were observed, and 
relatively few patients discontinued study treatment due to these AEs. Dose adjustment based on 
individual tolerability during the first 3 cycles substantially reduced the incidence of these AEs 
beyond Cycle 3, indicating the overall effectiveness of the approach to dose modification. These 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
9
TEAEs can be monitored routinely using standard assessments of hematological laboratory 
parameters, as is routine for patients with ovarian cancer receiving anticancer therapies. In the 
NOVA study, niraparib dose adjustment tended to occur early with most patients reaching their 
individual adjusted dose level at the end of Month 3 (ie, Cycle 3) of treatment.
Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been observed in 
patients receiving treatment with olaparib, a PARP inhibitor; given the common mechanism of 
action, MDS and AML therefore represent a potential risk to patients receiving niraparib. In the 
Phase 3 NOVA study, the incidence of MDS/AML in patients who received niraparib 
(5 of 367; 1.4%) was similar to its incidence in patients who received placebo (2 of 179; 1.1%). 
Guidance on monitoring patients for new AEs of MDS/AML and the follow-up of patients with 
suspected MDS/AML is provided.
Study PR-30-5011-C1 (NOVA corrected QT interval [QTc] substudy; n = 26) is an open-label 
evaluation of the effects of niraparib on QTc measurements in patients with histologically 
diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. There were no 
reports of clinically significant abnormal electrocardiogram (ECG) changes, including QTc 
interval prolongation, attributed to niraparib. Administration of niraparib at the therapeutic dose 
did not prolong the QT interval. There was no correlation between the exposure level (i.e., 
plasma concentration) of niraparib and QTc changes (i.e., change in corrected QT interval 
calculated using Frederica’s formula [ΔQTcF]). 
Baseline Platelet Count and Weight as Predictors of Thrombocytopenia.
An analysis was conducted using the data collected in ENGOT-OV16/NOVA and the initial 
phase I study, PN001. This analysis determined that baseline platelets had an impact on platelet 
nadir; lower baseline platelets (<180 109/L) were associated with an increased frequency of 
thrombocytopenia Grade ≥1 (76%) or Grade ≥ 3 (45%) compared to patients with higher 
baseline platelet counts. Further, an exploratory analysis of clinical data versus baseline body 
weight from ENGOT-OV16/NOVA was conducted.  For this analysis, the weight categories 
were based on quartiles with the lowest quartile (patients with a body weight less than 58 kg at 
baseline) compared to the highest quartile (patients with a body weight greater than or equal to 
77 kg at baseline).  While TEAEs occurred in most patients regardless of body weight, Grade ≥3 
TEAEs, SAEs, and TEAEs leading to dose modification or treatment discontinuation occurred 
more commonly in the weight <58 kg cohort than in the ≥77 kg cohort. In the cohort of patients 
with a body weight <58 kg, approximately 80% of patients had a dose reduction compared to 
59% of patients with a weight greater than or equal to 77 kg. Treatment discontinuations were 
increased in the subjects with lower body weight (24%) compared to patients in the highest 
quartile (10%).     
The potential relationship between body weight and TEAEs was further explored in an analysis 
to evaluate the correlation of grade 3 or 4 thrombocytopenia and baseline body weight.  The 
lowest platelet count in the first 30 days was plotted versus baseline body weight to determine if 
low body weight identified a subgroup of patients with higher levels of thrombocytopenia during 
Cycle 1.  In the first 30 days of treatment, a baseline body weight >77 kg is associated with a 
lower incidence of grade 3 or 4 thrombocytopenia (14%) relative to the group with body weight 
<58 kg (43%). 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
10
Finally, a classification tree approach was used to refine the best cut-off points for predicting the 
likelihood of a patient developing ≥Grade 3 thrombocytopenia within 30 days after the first dose 
of niraparib.  The results of the model show that the subgroup of patients with a baseline body 
weight <77 kg or baseline platelet count <150,000 µL had a grade 3/4 thrombocytopenia rate in 
the first 30 days of 35.4% compared to 11.5% in the group of patients with a body weight >77 kg 
and a platelet count >150,000 µL. Further, the average daily dose was 258 mg through the first 
two cycles for patients with a body weight >77 kg and platelet count >150,000 µL, and was only 
206 mg for patients with body weight < 77 kg or platelet count <150,000 µL. Thus, the actual 
delivered dose approximated a starting dose of 200 mg despite the intended delivery of a starting 
dose of 300 mg. These observations are to be confirmed in the present study with the inclusion of 
study treatment dosed at 200 mg (2 capsules of niraparib or placebo) in patients whose baseline 
weight is <77 kg or baseline platelet count is <150,000 µL.
2.3
Dostarlimab
Dostarlimab (TSR-042) is an IgG4-k humanized monoclonal antibody that binds with high 
affinity to PD-1 resulting in inhibition of binding to PD-L1 and PD-L2. This antibody was 
generated based on a proprietary platform that utilizes affinity maturation to select antibodies 
with desired functional characteristics. The functional antagonist activity of dostarlimab was 
confirmed in a mixed lymphocyte reaction (MLR) demonstrating enhanced interleukin-2 
production upon addition of  dostarlimab. Furthermore,  dostarlimab has an acceptable safety 
profile based on toxicology studies in cynomolgus monkeys. Based on the  dostarlimab 
preclinical data,  dostarlimab is expected to result in similar clinical benefit in patients with a 
variety of tumors with results similar to antibodies of the same class (nivolumab and 
pembrolizumab) and thus dostarlimab is being evaluated clinically as an immunotherapy for 
advanced malignancies. 
Clinical Experience 
As of the clinical cutoff date of 21 January 2020 there were 4 ongoing Phase 1 studies, 3 ongoing 
Phase 2 studies, and 2 ongoing Phase 3 studies with dosarlimab. Study 4010-01-001 is a first-in-
human study of dostarlimab to evaluate the safety and tolerability, PK, PDy, and clinical activity 
of dostarlimab in subjects with recurrent or advanced solid tumors. Dose escalation in Part 1 of 
the study continued to a maximally administered dose of 10 mg/kg Q2W and a MTD was not 
identified. No DLTs were observed in Part 1. Following completion of Part 1, Part 2A evaluated 
safety and tolerability of dostarlimab at 2 fixed dosing schedules of 500 mg Q3W and 1,000 mg 
Q6W. No DLTs were observed in Part 2A.
Dostarlimab Monotherapy
Study 4010-01-001 is an ongoing, first-in-human Phase 1 study of  dostarlimab to evaluate the 
safety and tolerability, PK, pharmacodynamics (PDy), and clinical activity of  dostarlimab in
patients with recurrent or advanced solid tumors. A total of 21 subjects were dosed in the dose
escalation phase of the study (Part 1). Dose escalation continued to a maximally administered
dose of 10 mg/kg every 2 weeks (Q2W) and a maximum tolerated dose (MTD) was not

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
11
identified. No dose-limiting toxicities (DLTs) were observed. The PK of  dostarlimab were
dose-proportional across the dose range tested. Receptor occupancy was measured by direct
binding of  dostarlimab to PD-1 on T cells from subjects participating in Part 1 and by the
 dostarlimab-induced inhibition of interleukin-2 (IL-2) production after ex vivo stimulation of
T cells from subjects participating in Part 1. Maximal receptor occupancy was achieved at all
doses tested down to dostarlimab plasma concentrations as low as 2.435 μg/mL, and was
maintained for approximately 29 days. The PK/PDy data was used to determine the flat dosing
tested in Part 2A of the study. In this phase of the study, the safety and tolerability of dostarlimab
was evaluated at 2 fixed dosing schedules: 500 mg every 3 weeks (Q3W) and 1,000 mg every
6 weeks (Q6W). No DLTs were observed in Part 2A. The recommended Phase 2 dose (RP2D)
regimen was determined to be 500 mg Q3W for 4 cycles followed by 1,000 mg Q6W for all
cycles thereafter, which is being evaluated in expansion cohorts for microsatellite instability-high
(MSI-H) and microsatellite stable (MSS) endometrial cancer, non-small cell lung cancer
(NSCLC), and non-endometrial MSI-H or polymerase ε-mutated cancer in Part 2B of study. The
PK/PDy profile of subjects participating in Part 2B of the study was similar to that of subjects
participating in Part 2A of the study.
Overall TEAEs in subjects who received dostarlimab monotherapy are summarized in Table 10.
As of the data cutoff date, 527 subjects (98.5%) who were treated with dostarlimab monotherapy 
reported at least 1 TEAE. The overall incidence of subjects with study drug-related TEAEs was 
67.5% (n=361). The majority of study drug-related TEAEs had a severity of Grade 1 or 2. Study 
drug-related TEAEs of ≥Grade ≥3 were reported in 70 subjects (13.1%). Serious TEAEs were 
reported in 205 subjects  (38.3%), and 39 subjects (7.3%) had serious TEAEs assessed to be 
study drug-related (definitely related, related, or possibly related) by investigators. Forty-eight 
subjects (9.0%) discontinued study drug due to a TEAE. TEAEs leading to study drug 
discontinuation were assessed as study drug-related by the investigator for 25 subjects (4.7%). 
Sixteen subjects (3.0%) had a TEAEs leading to death; none were assessed as study drug-related 
by the investigator.
The most commonly reported TEAEs (˃20%) with dostarlimab monotherapy were fatigue
(25.6%), nausea (24.9%), anaemia (23.6%), and diarrhoea (21.5%). The majority of the ≥Grade 
3 events occurred in 2% of subjects or less each, with the exception of anaemia (8.6%), dyspnoea 
(3.7%), abdominal pain (3.4%), fatigue (2.8%), hyponatraemia (2.8%), and pulmonary embolism 
(2.4%). The TEAEs occurring in at least 10% of subjects receiving dostarlimab monotherapy 
were generally considered not to be related to the study drug (ie, < 50% of TEAEs were related). 
Exceptions were the events of fatigue, pruritus, diarrhoea, fatigue, asthenia, and arthralgia: > 
50% of these events were considered to be study drug-related.
As of July 2017, 32 of 34 subjects treated with  dostarlimab monotherapy in Part 1 and Part 2A 
of Study 4010-01-001 had at least 1 post-baseline tumor assessment. Two subjects achieved a
partial response: 1 subject with ovarian cancer who was treated with  dostarlimab at 3 mg/kg 
followed by  dostarlimab at 10 mg/kg and 1 subject with small cell lung cancer who was treated 
with  dostarlimab at 10 mg/kg. Seven subjects achieved stable disease.
Dostarlimab Combination Therapies

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
12
Study 4020-01-001 is an open-label, first-in-human Phase 1 study of TSR-022, an anti-TIM3
antibody, that is being conducted in 2 parts in patients with advanced solid tumors. In Part 1C,
 dostarlimab is administered in combination with TSR-022 to establish the RP2D regimen for 
this study drug combination. In Part 2 of the study, the efficacy of TSR-022 ±  dostarlimab is 
evaluated in patients with advanced solid tumors (expansion cohorts for melanoma, NSCLC, or 
colorectal cancer). 
Study 3000-01-002 is an open-label, Phase 1b study of  dostarlimab that is being conducted in 4 
parts in patients with advanced or metastatic cancer. The study evaluates DLTs, safety, and 
tolerability of  dostarlimab in combination with niraparib ± bevacizumab or carboplatin and 
paclitaxel ± bevacizumab. At the time of data cutoff, only Part A ( dostarlimab in combination 
with niraparib) and Part B ( dostarlimab in combination with carboplatin and paclitaxel) had 
subjects enrolled.
Study 4040-01-001 is an open-label, first-in-human Phase 1 study of TSR-033, an anti-LAG3
antibody, that is being conducted in 2 parts in patients with advanced solid tumors. In Part 1C,
dostarlimab is administered in combination with TSR-033 to establish the RP2D regimen for this
study drug combination. In Part 2 of the study, the efficacy of TSR-022 ±  dostarlimab is 
evaluated in patients with advanced solid tumors (expansion cohorts for epithelial ovarian 
cancer, triple-negative breast cancer, and urothelial carcinoma). At the time of data cutoff, no 
subjects in this study had received dostarlimab. 
A total of 51 subjects with heavily pretreated advanced solid tumors have been treated with 
dostarlimab in combination with other therapeutic agents: 28 subjects received  dostarlimab in 
combination with TSR-022 in Study 4020-01-001, 9 subjects received  dostarlimab in 
combination with niraparib in Part A of Study 3000-01-002, and 14 subjects received  
dostarlimab in combination with carboplatin and paclitaxel in Part B of Study 3000-01-002. The 
majority (80.4%) of subjects receiving  dostarlimab combination therapy reported at least 1 
TEAE, with events of fatigue and dyspnea being the most frequently reported. One DLT (Grade 
3 aspartate aminotransferase increased) was reported in a subject in Part B of Study 3000-01-
002. 
Serious AEs occurred in 14 subjects, none of these events were considered study drug-related.
One subject had at least 1 AE leading to study drug discontinuation (alanine aminotransferase
increased and aspartate aminotransferase increased). Both events were considered study
drug-related. No subject had an AE leading to death.
2.4
Radiation Therapy
2.4.1
Proton Beam Radiation Therapy
There have been unprecedented efforts in radiation oncology to develop and use sophisticated, 
conformal photon techniques in order to improve the outcome for cancer patients. The aim of 
these new techniques is to concentrate the radiation dose distribution more completely on the 
disease target, thereby sparing critical normal tissues and increasing the target dose. Toward this 
end, many advances have been made and examples of new developments include tomotherapy 
and intensity modulated photon therapy. At the same time, heavy, charged-particle programs, 
particularly those for proton therapy, have been developed. Proton therapy dose distributions are 
superior to those of photon therapy and this provides the potential to further improve clinical 
outcomes. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
13
2.4.1.1
Characteristics of Proton Beams
The basis for the advantages of proton beams lies in the physical laws that determine the 
absorption of energy in tissues exposed to photon or proton beams. In a specific tissue, photons 
are absorbed exponentially whereas protons have a finite range dependent upon the initial proton 
energy. Therefore, the depth dose characteristics of the two beams are qualitatively different. 
Protons lose their energy in tissue mostly by coulombic interactions with electrons in the 
constituent atoms; however, a small fraction of energy is transferred through nuclear collisions. 
The energy loss per unit path length is relatively small and constant as the proton traverses the 
tissue until near the end of the proton range where the residual energy is lost over a short 
distance (approximately 0.7 cm in width at 80% of the maximum dose) and the proton comes to 
rest, resulting in a distinctive sharp rise in the tissue absorbed dose (energy absorbed per unit 
mass) - known as the Bragg peak. In physical terms, the magnitude of the transfer of energy to 
tissue per unit path length traversed by the protons is inversely proportional to the square of the 
proton velocity. The low dose region between the entrance and the Bragg peak is called the 
plateau of the dose distribution and the dose there is 30-40 percent of the maximum dose.
The Bragg peak is too narrow in extent to irradiate any but the smallest of targets, ablation of the 
pituitary gland for example. For the irradiation of larger targets/tumors the beam energy is 
modulated - several beams of closely spaced energies (ranges) are superimposed to create a 
region of uniform dose over the depth of the target. These extended regions of uniform dose are 
called "spread-out Bragg peaks" (SOBP).
In the usual clinical situation, more than one radiation beam is used in both x-ray and proton 
treatments. However, the advantage shown for protons using single beams is present for each and 
every beam used. Therefore, one cannot overcome the physical disadvantage of x-rays by the use 
of multiple beams or complex beam arrangements. In modern proton therapy facilities, which 
have isocentric gantries and sophisticated beam delivery and control systems, proton therapy 
capabilities are equivalent to those for state-of-the-art, conformal therapy using x- rays with 
respect to numbers of beams, beam directions and complex delivery techniques such as intensity 
modulation. 
2.4.1.2
Intensity Modulated Radiation Therapy
Intensity-modulated x-ray therapy (IMXT) – the use of x-ray beams each of which is purposely 
made non-uniform over its cross-section – provides a new degree of freedom in treatment 
delivery and can lead to more conformal dose distributions. Protons, too, can be used in an 
intensity modulated mode (IMPT) similar to that for photons and, in an additional degree of 
freedom, are also made non-uniform in depth. The advantage that single beams of protons have 
over single beams of x-rays, which is maintained when multiple cross-firing beams of uniform 
intensity are employed, is similarly maintained when intensity modulation is employed. 
In IMXT, the dose can be made to conform to the target volume while avoiding selected adjacent 
sensitive structures (although the dose uniformity within the target volume is strongly influenced 
by such selective avoidance and is often of undesirable magnitude). However, IMXT does not 
reduce the integrated dose delivered outside the target volume (as compared to standard 
conformal photon therapy); it only, in general, spreads that energy out over a larger volume. In 
our treatment planning intercomparisons (in nasopharynx, paranasal sinus, lung and Ewing’s 
sarcoma) we have found that the integral dose for IMPT is a factor of two (on the average) less 
than for IMXT. Moreover, whatever improvement IMXT achieves over standard conformal x-

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
14
ray therapy, a comparable improvement is achieved when IMPT is compared to standard 
conformal proton therapy.
Pancreatic tumors have a number of normal structures in close proximity that have limited 
radiation tolerance including kidneys, liver, spinal cord, and stomach. The lack of exit dose from 
proton beam radiation can allow for reduced dose to these and other normal tissues. 
2.4.2
Photon-based short course chemoradiation in pancreatic cancer
Dholakia and colleagues (2013) studied fractionated stereotactic body radiation therapy (SBRT) 
of 33 Gy photons in five fractions for locally advanced pancreatic cancer. They demonstrated 
local control of 83% at one year with minimal acute or late gastrointestinal toxicity and favorable 
survival compared to historical data.  
2.5
Rationale
Niraparib is a potent inhibitor of PARP and given the immunomodulatory and radio-sensitizing 
effects of PARP inhibitors, we propose a combination of niraparib and  dostarlimab with 
radiation. This may induce a synergistic anti-neoplastic effect, thus providing an opportunity for 
the expanded use of PARP inhibitors. 
We hypothesize that with radiation, there will be efficacy of niraparib and  dostarlimab in 
unselected metastatic pancreatic We plan to determine the safety and efficacy of niraparib and  
dostarlimab with XRT as well as correlative genomic and functional studies. 
2.6
Correlative Studies Background
This study will incorporate correlative studies leveraging serial tumor biopsies and serial blood 
collection. We will explore the significance in DDR genes including, but not limited to BRCA1, 
BRCA2, PALB2, FANCD2, ATM, ATR, and CHEK2. 
Centromeric and pericentromeric heterochromatin is comprised of large tandem arrays of 
repetitive elements called satellites, and these regions are known to be differentially methylated 
in a variety of malignancies (Jurka 2005). Analysis of all human satellites identified striking 
differential expression of certain satellite repeats in cancers (black) compared to normal tissues 
(white). The ALR, HSATII, and CATTCn satellites were found to be elevated in a wide variety 
of cancers including pancreatic, prostate, lung, ovarian, and renal cell carcinomas compared to 
normal tissues (Ting 2011). Out of these, HSATII was the most specific for cancer (Fig. 1, inset), 
and using RNA in situ hybridization (RNA-ISH) 
we confirmed high expression of this repeat 
across approximately 600 epithelial cancers 
including carcinomas of the pancreas, lung, 
prostate, breast, thyroid, and colon (Fig. 1). 
Interestingly, the expression of HSATII was 
found to be elevated in preneoplastic lesions 
indicating a potential importance in 
tumorigenesis. In addition, a growing amount of 
Fig. 1: HSATII RNA-ISH of human primary colon 
cancer, (Red dots = HSATII, Hematoxylin = blue 
nuclear counter stain). 200x magnification 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
15
literature indicates that these repeat RNAs are linked with DNA damage pathways and linked 
with the ATR (Flynn 2015) and BRCA (Zhu 2011) pathway. This would indicate that repeat 
RNAs may serve as a novel biomarker of DNA damage response and potentially a predictive 
biomarker of response to DNA damaging agents including niraparib and/or radiation.
More recently, we have discovered that satellite repeats behave similar to other endogenous 
retroviral elements as they are actively reverse transcribed in cancers (Bersani 2015) and they are 
enriched for specific CpG sequence motifs that are features usually associated with pathogen 
genomes (Greenbaum 2014, Greenbaum 2008, Greenbaum 2009). These features are capable of 
engaging pattern recognition receptors (PRRs) of the innate immune system and activating 
associated pathways. Many of the 
satellites (Fig. 2 red dots), were indeed 
divergent from other RNA species, but 
again the HSATII satellite had an 
exceptionally unique sequence content 
with highly anomalous CpG usage and 
low UpA compared to all other known 
non-coding RNAs in the human 
transcriptome (Fig. 2) (Tanne 2015). 
This anomalous CpG usage was 
similarly found in the mouse major 
satellite GSAT demonstrating common 
sequence motif usage between species 
despite having completely divergent 
sequences. Based on previous analyses 
in viruses, this CpG usage in satellite 
RNA was shown to initiate PRR 
signaling and trigger a robust innate 
immune response. Altogether, repeat 
RNAs can serve as novel biomarkers of DNA damage agents in the setting of immunotherapy.
In addition to the tissue based analyses, this study will also incorporate blood based assessments
of circulating tumor DNA (ctDNA) and peripheral blood T-cell Receptor (TCR) repertoire. 
These analyses will provide systemic measures of tumor and immune response that will
complement the studies performed on tumor tissue. Furthermore, whole exome sequencing of
baseline and progression ctDNA may help identify novel mechanisms of therapeutic resistance to
dual checkpoint pathway blockade, which could provide critical guidance for the development of
future therapeutic strategies.
2.7
Patient Reported Outcomes Background
Studying patients’ symptom burden and QOL while they are participating in a clinical trial 
provides an opportunity to better understand their disease- and treatment-related outcomes. 
Patients’ symptom burden and QOL are better indicators of their treatment tolerability than 
clinician-reported toxicity monitoring. Combining objective endpoints, such as response rate, 
with subjective patient-reported outcomes has become increasingly important in determining 
Fig. 2: Distribution of UpA and CpG bias in ncRNA 
taken from cancer (red) and GENCODE (gray). Each 
ellipse indicates one standard deviation from the mean 
value in GENCODE. HSATII has unusual CpG usage.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
16
efficacy, toxicity, and safety and for allowing comparisons across treatment arms (Edgerly). 
Additionally, evaluating patient-reported measures may help highlight patients’ difficulties with 
treatment adherence by demonstrating additional side effects and toxicities of therapy (Berry). 
Increased attention to patients’ symptom burden and QOL while they are participating in a 
clinical trial provides an opportunity to improve their quality of care (Oberguggenberger, 
Meyers). Thus, we aim to describe QOL, symptom burden and mood in this study population to 
help us better identify the side effects and challenges faced by patients with pancreatic cancer.
We will use the PRO-CTCAE and the Functional Assessment of Anorexia/ Cachexia (FAACT) 
to measure patient quality of life. The PRO-CTCAE is a patient-reported outcome measurement 
system developed to evaluate symptomatic toxicity in patients on cancer clinical trials. It was 
designed to be used as a companion to the Common Terminology Criteria for Adverse Events 
(CTCAE),  the standard dictionary for adverse event reporting in cancer clinical trials.
The Functional Assessment of Anorexia/Cachexia Treatment (FAACT), part of the FACIT 
Measurement System, is composed of the FACT-G and the anorexia/cachexia subscale (A/CS). 
The FACIT Measurement System is a collection of QOL questionnaires targeted to the 
management of chronic illness. The FACT-G  is a 27-item compilation of general questions 
divided into four primary QOL domains: Physical Well-Being, Social/Family Well-Being, 
Emotional Well-Being, and Functional Well-Being. It is considered appropriate for use with 
patients with any form of cancer and has also been used and validated in other chronic illness 
condition.
3. PARTICIPANT SELECTION
3.1
Inclusion Criteria 
Participants must meet the following criteria on screening examination in order to be eligible to 
participate in this study:
3.1.1
Histologically or cytologically confirmed metastatic adenocarcinoma of pancreatic 
origin.
3.1.2
Age > 18 years.  
3.1.3
ECOG performance status ≤ 1.
3.1.4
Life expectancy of greater than 3 months. 
3.1.5
Participants must have normal organ and marrow function as defined below:

leukocytes
≥ 2,000/mcL

absolute neutrophil count
≥ 1,500/mcL

platelets
≥ 100,000/mcL

hemoglobin
≥ 9 g/dL

AST(SGOT)/ALT(SGPT)
≤2.5 × institutional upper limit of normal(subjects with 
liver metastases can have an AST (SGOT) ≤ 5 x ULN

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
17

creatinine
≤ 1.5 x ULN 
OR

creatinine clearance*
≥ 60 mL/min (if using the Cockcroft-Gault formula)

total bilirubin
≤ 1.5 x ULN (subjects with Gilbert Syndrome can have 
a total bilirubin < 3 x ULN)
*Creatinine clearance should be calculated per the following:
CrCl (mL/min) = (140 – age [years]) x weight [kg] x 1.23 (x 0.85 if female) . 
Serum creatinine (micromol/L)
3.1.6
Women of childbearing potential (WoCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days 
prior to initiating protocol therapy.
Nonchildbearing potential is defined as follows (by other than medical reasons):

≥45 years of age and has not had menses for >1 year

Patients who have been amenorrhoeic for <2 years without history of a hysterectomy 
and oophorectomy must have a follicle stimulating hormone value in the 
postmenopausal range upon screening evaluation

Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented 
hysterectomy or oophorectomy must be confirmed with medical records of the actual 
procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with 
medical records of the actual procedure, otherwise the patient must be willing to use 
2 adequate barrier methods throughout the study, starting with the screening visit 
through 180 days after the last dose of study treatment. See Section 4.4 for a list of 
acceptable birth control methods. Information must be captured appropriately within 
the site’s source documents. Note: Abstinence is acceptable if this is the established 
and preferred contraception for the patient.
3.1.7
Women of childbearing potential must agree to use appropriate method(s) of 
contraception. WOCBP should use an adequate method to avoid pregnancy for 6 
months (30 days plus the time required for niraparib to undergo five half-lives/180 
days) after the last dose of investigational drug. 
3.1.8
Women must not be breastfeeding during the study or for 180 days after the last dose of 
investigational drug.
3.1.9
Men who are sexually active with WoCBP must use any contraceptive method with a 
failure rate of less than 1% per year. Men receiving protocol therapy and who are 
sexually active with WoCBP will be instructed to adhere to contraception for a period 
of 6 months (180 days) after the last dose of investigational product. 
(Women who are not of childbearing potential, i.e. are postmenopausal as defined in 
the eligibility criteria or surgically sterile, as well as azoospermic men do not require 
contraception.)

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
18
3.1.10 Ability to understand and the willingness to sign a written informed consent document
3.1.11 If applicable, stable dose of dexamethasone of 10mg or less for 4 weeks prior to 
initiation of investigational protocol therapy. Regimen must be completed >14 days 
prior to treatment start.
3.1.12 One previously unirradiated measurable lesion > 1 cm in size amenable to radiotherapy 
at a dose of 8 Gy x 3 and can meet dose constraints, and another unirradiated 
measurable lesion > 1 cm in size outside the radiation field that can be used as 
measurable disease.
3.1.13 Patients must have had at least one line of prior treatment. Any prior line of treatment is 
permitted, including adjuvant. 
3.2
Exclusion Criteria
Participants who meet any of the following criteria will be excluded:
3.2.1
Systemic anticancer or biological therapy including prior chemotherapy, 
immunotherapy, targeted small molecule therapy within 14 days prior to investigational 
agent, or those who have not recovered (i.e., ≤ grade 1 or at baseline) from adverse 
events due to agents administered more than 2 weeks earlier. Participants with ≤ grade 
2 neuropathy are an exception to these criteria and may qualify for the study. If the 
participant received major surgery, then they must have recovered adequately from the 
toxicity and/or complications from the intervention prior to starting therapy.
3.2.2
Received investigational therapy < 4 weeks, or within a time interval less than at least 5 
half-lives of the investigational agent, whichever is shorter, prior initiating protocol 
therapy.
3.2.3
Major surgery ≤ 3 weeks prior to initiating protocol therapy and/or not recovered from 
any surgical effects.
3.2.4
Received radiation therapy encompassing >20% of the bone marrow within 2 weeks; or 
any radiation therapy within 1 week prior to day 1 of protocol therapy. 
3.2.5
Received a transfusion (platelets or red blood cells) ≤ 4 weeks prior to initiating 
protocol therapy
3.2.6
Received colony-stimulating factors (e.g., granulocyte colony-stimulating factor, 
granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) 
within 4 weeks prior to initiating protocol therapy. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
19
3.2.7
Known history of Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior 
chemotherapy that persisted > 4 weeks and was related to the most recent treatment. 
3.2.8
Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia 
(AML). 
3.2.9
Active, known or suspected autoimmune disease that has required systemic treatment 
within the past 2 years other than vitiligo, type I diabetes mellitus, residual 
hypothyroidism due to autoimmune condition only requiring hormone replacement, 
psoriasis not requiring systemic treatment, or conditions not expected to recur in the 
absence of an external trigger.
3.2.10 Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily 
prednisone equivalents) or other immunosuppressive medications within 14 days of 
study drug administration. Inhaled or topical steroids and adrenal replacement doses > 
10 mg daily prednisone equivalents are permitted in the absence of active autoimmune 
disease. Participants are permitted to use topical, ocular, intraarticular, intranasal, and 
inhalational corticosteroids (with minimal systemic absorption). Physiologic 
replacement doses of systemic corticosteroids are permitted, even if > 10 mg/day 
prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast 
dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type 
hypersensitivity reaction caused by contact allergen) is permitted.
3.2.11 Known history of active TB (Bacillus Tuberculosis). Testing is not required for 
eligibility purposes. 
3.2.12 Known hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic 
acid (HCV antibody) indicating acute or chronic infection. Testing is not required for 
eligibility purposes.  
3.2.13 Known history of testing positive for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS). These participants are at increased risk 
of lethal infections when treated with marrow suppressive therapy. Testing is not 
required for eligibility purposes. 
3.2.14 Known ≥ Grade 3 immune-related AE with prior immunotherapy, with the exception of 
non-clinically significant lab abnormalities. 
3.2.15 Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, recent (within 90 days) myocardial infarction or psychiatric illness/social 
situations that would limit compliance with study requirements.
3.2.16 Known psychiatric or substance abuse disorders that would interfere with cooperation 
with the requirements of the trial.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
20
3.2.17 Known additional malignancy diagnosed, detected or treated ≤ 2 years prior to 
initiation of protocol therapy . Exceptions include basal cell carcinoma of the skin and 
squamous cell carcinoma of the skin that has undergone potentially curative therapy or 
in situ cervical cancer.
3.2.18 Known history of, or any evidence of active, non-infectious pneumonitis or interstitial 
lung disease. (Grade 1 asymptomatic pneumonitis is allowed if found during baseline 
CT scanning unless it is thought to be clinically relevant).
3.2.19 Active infection requiring systemic therapy
3.2.20 Has received a live vaccine within 30 days of planned start of study therapy. Note: 
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are 
allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated 
vaccines, and are not allowed.
3.2.21 Known hypersensitivity to niraparib and dostarlimab components or excipients.
3.2.22 History of severe hypersensitivity reaction to any monoclonal antibody
3.2.23 Participants with known brain metastases should be excluded from this clinical trial 
because of their poor prognosis and because they often develop progressive neurologic 
dysfunction that would confound the evaluation of neurologic and other adverse events. 
Further imaging is not required for eligibility purposes. 
3.3
Inclusion of Women and Minorities
We do not expect the inclusion and exclusion criteria to either over or under represent women, 
minorities, or underrepresented populations. 
4. REGISTRATION PROCEDURES
4.1
General Guidelines for DF/HCC Institutions
Institutions will register eligible participants in the Clinical Trials Management System (CTMS) 
OnCore. Registrations must occur prior to the initiation of any protocol-specific therapy or 
intervention. Any participant not registered to the protocol before protocol-specific therapy or 
intervention begins will be considered ineligible and registration will be denied.
An investigator will confirm eligibility criteria and a member of the study team will complete the 
protocol-specific eligibility checklist.
Following registration, participants may begin protocol-specific therapy and/or intervention. 
Issues that would cause treatment delays should be discussed with the Overall Principal 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
21
Investigator (PI). If the subject does not receive protocol therapy following registration, the 
subject must be taken off-study in the CTMS (OnCore) with an appropriate date and reason 
entered.
4.2
Registration Process for DF/HCC Institutions
Applicable DF/HCC policy (REGIST-101) must be followed.  
5. TREATMENT PLAN
The intervention in this study is a combination of niraparib, dostarlimab, and radiation therapy.
 
This is a two-stage single-arm study. Participants will receive one cycle of niraparib + 
dostarlimab followed by a second cycle during which radiation therapy will also be given, 
followed by repeating cycles of niraparib/dostarlimab until the participant is taken off-therapy. 
There is no required order for dostarlimab, Niraparib or radiation therapy. 
No investigational or commercial agents other than niraparib, dostarlimab and radiation therapy 
may be administered with the intent to treat the participant’s malignancy. 
5.1
Drug Therapy
5.1.1
Niraparib
Niraparib will be given orally (PO) at a dose of 200 mg daily. Dosing will commence on cycle 1 
day 1 and will continue until the participant is taken off treatment (criteria in section 5.6, below). 
Niraparib may be taken with or without food. Niraparib will be dispensed to participants at the 
start of each cycle. If niraparib is dose reduced, participant should continue to use current supply 
until their supply is exhausted.  Missed or vomited doses should not be made up. If a participant 
misses a dose (greater than 12 hours from normal dosing time) of niraparib, they should skip that 
dose and take their next dose at its regularly scheduled time.
21 consecutive days is one treatment cycle for the first four cycles.  Beginning with cycle 5, each 
cycle will last 42 days. Treatment will be administered on an outpatient basis, unless the 
participant is hospitalized. 
The participant will be asked to maintain a medication diary of each dose of niraparib. The diary 
will be returned to the clinic staff at the end of each cycle or the beginning of the next cycle. 
For safety monitoring, CBC should be drawn weekly during the first two cycles of Niraparib as 
indicated in Section 10, Study Calendar. Labs can be drawn at local hospitals if necessary. Blood 
pressure and heart rate monitoring will be required weekly for the first 2 months of therapy (until 
C3D15). After the first 2 months of therapy, blood pressure and heart rate monitoring must be 
checked monthly for the first year. For the weekly checks, monitoring at or near home is 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
22
acceptable.
5.1.2
Dostarlimab
Dostarlimab will be administered via a 30-minute IV infusion (with a -5 and +15-minute window 
permitted). Dosing will be 500mg every 3 weeks for the first 4 doses followed by 1000mg every 
6 weeks for all subsequent cycles. Therefore, dosing is as follows: 

500mg on C1D1

500 mg on C2D1

500 mg on C3D1

500 mg on C4D1

1000 mg on C5D1

1000 mg on C6D1

Continuing with 1000 mg on the first day of each 42 day cycle until participant meets 
criteria in section 5.6, below. 
The visit window for administration is +/- 7 days unless treatment is delayed for toxicity 
management. However, it is recommended that participants be kept on the original dosing 
scheduled based on C1D1 and maintain the dosing intervals as closely as possible to Q3W then 
Q6W.
In the case of an infusion-related reaction, please refer to section 6.2 Table 2, below, for 
treatment guidelines. 
5.2
Radiation Therapy
Participants will receive 24 Gy given as 3 fractions of 8 Gy every other day or 2 days as needed. 
Treatment delays due to holidays will not constitute a protocol violation. Radiation will begin on 
Cycle 2 Day 1.  It is not required radiation begin on a Monday. 
5.2.1
Dose Specifications: 3D Conformal Radiotherapy (3DCRT), IMRT, Protons
Dose will be prescribed such that at least 80% of the PTV receives the prescription dose and will 
be scored as per protocol. The maximum allowable dose within the PTV is 120% of the 
prescribed dose. The minimum allowable dose within the PTV is >80% of the prescribed dose to 
a volume that is at least 0.1 cc. Safety should be prioritized, and underdosing at the periphery of 
the PTV is allowed to meet the dose constraints below.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
23
Participants treated entirely via EBRT shall receive prescription doses to the PTV (with the 
above constraints). All attempts should be made to deliver the PTV dose with the above 
heterogeneity constraints with adherence to the critical structure parameters listed below. 
See Section 5.2.5 below for specifics regarding when to implement a dose reduction. The final 
prescription dose will be reported specifically to the study coordinator and recorded on a patient-
by-patient basis.
Dose constraints
Liver- V15< 700 cc
Brachial plexus- Dmax < 24 Gy
Trachea/Bronchus – Dose to 4cc < 14 Gy, Dmax < 24 Gy
Lung- V9<1500 cc, V11<1000cc
Trachea/Large bronchus- Max dose 
Spinal cord-  DMax < 18 Gy, Dose to 1.2 cc < 16 Gy
Mucosal surface (including esophagus, stomach, bowel) – Dmax < 15 G
5.2.2
Technical Factors
Photon RT will be delivered with megavoltage equipment at energies ≥6 MV, capable of daily 
image guidance; with multileaf collimator for intensity modulated radiation therapy is required. 
Inverse-planned IMRT, forward planned IMRT, VMAT, and 3D CRT are permitted.
Proton delivery system must deliver protons of sufficient energy to cover the target.
5.2.3
EBRT Localization, Simulation, and Immobilization
Simulation will be CT-based in all cases. The use of contrast at the time of simulation is 
recommended but not required. Participants will be positioned on a flat tabletop with a 
customized immobilization for stabilization and setup reproducibility. CT images should be 
acquired at a slice thickness of ≤3 mm. Target volumes and normal critical structures will be 
defined in the slices in which they are visualized. The 3DCRT cases must utilize “beam’s eye 
view” representations to define final beam aperture.
4Dimensional CT scan is required for liver and lung lesions.
5.2.4
Treatment Planning / Target Volumes
The definition of volumes will be in accordance with the ICRU Report #50: Prescribing, 
Recording, and Reporting Photon Beam Therapy.
The Gross Tumor Volume (GTV) is defined by the physician as all known disease as defined by 
the planning CT.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
24
The Clinical Target Volume (CTV) is the GTV plus areas considered to contain microscopic 
disease, delineated by the treating physician.  0-10 mm expansion may be used at the discretion 
of the treating physician.
The Planning Target Volume (PTV) will provide a margin around the CTV to compensate for 
the variability of treatment set up and internal organ motion. A range of 5-10 mm around the 
CTV is required to define each respective PTV. Superior and inferior margins (capping) should 
be 5-10 mm depending on the thickness and spacing of the planning CT scan. Careful 
consideration should be made when defining the 5-10 mm margin in 3 dimensions.
The ICRU Reference Points are to be located in the central part of the PTV and, secondly, on or 
near the central axis of the beams. Typically these points should be located on the beam axes or 
at the intersection of the beam axes.
Normal Critical Structures will be defined on the treatment planning CT scan and all structures 
will be contoured in their entirety as solid organs. See the ITC web site (http://atc.wustl.edu) to 
view examples of target and normal tissue contours.
The PTV forms the entire target as described. 3D conformal beams will be shaped to include the 
entire PTV and minimize dose to surrounding critical structures as described. Intensity 
modulated radiotherapy (IMRT) using inverse planning is permitted with constraints placed to 
adhere to critical structure dose limitations as defined above.
5.2.5
Critical Structures
Critical structure dose constraints shall remain consistent with Section 5.2.1, above. While every 
effort should be made to deliver prescription doses to the PTV as specified while adhering to 
these constraints, it is recognized that certain anatomical factors may prevent this.
For purposes of compliance, up to a 5% absolute increase in the volume of critical structure 
receiving greater than the specified dose will be considered “variation acceptable,” without a 
protocol deviation. Any increase in critical structure volume greater than 5% receiving more than 
the specified dose will be considered a “deviation unacceptable”.  It is at this point that a 
reduction in coverage should be considered.
5.2.6
Treatment Verification
First day port films or portal images of each field along with orthogonal isocenter verification 
films (or images) must be obtained. If modifications are made in field shaping or design, a port 
film of each modified field along with orthogonal isocenter verification films (or images) is 
required on the first day’s treatment of that field. Thereafter, weekly verification films or images 
of orthogonal isocenter views (anterior to posterior and lateral projection) are required.
For IMRT, the intensity profiles of each beam must be independently verified and compared to 
the planned field intensity. Portal films are not required for IMRT, but orthogonal verification 
films are required, just as for 3DCRT. These images are to be archived by the institution for later 
review if requested by the study chair.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
25
Daily on-line target localization (kV or MV imaging with fiducials, trans-abdominal ultrasound, 
or other) or off-line adaptive approaches to account for interfraction organ motion and setup 
variability are permitted on this study but not required. The use of image guidance or daily target 
localization including the specific type implemented must be documented by the treating 
physician and submitted to study headquarters.
Management of Radiation Dose to the Patient from Daily Localization
According to the literature, the estimates of patient dose per imaging study for various imaging 
systems vary considerably. The doses are in the range of 0.1 cGy BrainLab’s ExacTrac planar 
kV-systems and can be considered negligible compared with doses from MV portal imaging and 
kV and MV CT. The doses from helical MV CT scans on a Tomotherapy unit are estimated to be 
in range from 1 to 3 cGy, similar to doses reported for kV cone beam CT on Elekta Synergy 
machine. The doses for MV cone beam CT vary from 1 cGy to 10 cGy depending on the field 
size. Thus, the doses for 3D imaging systems used one time each day are in the range of 0.1 to 10 
cGy and can contribute from 0.06 to 6% to a daily dose of 1.8 Gy. As a technique of controlling 
participant dose, it is recommended that a QA procedure be established at each institution to 
verify the accuracy of the image registration software on a daily basis. This QA check should be 
performed by the therapists operating a particular treatment device and is aimed at reducing the 
use of repeat imaging to check that the registration software has functioned properly when a shift 
of participant position is carried out. Additionally, it is not recommended that an institution use a 
daily imaging technique that delivery greater than 3 cGy/dy to the patient. This limit dictates that 
repeat imaging on a particular day is held to a minimum when systems that deliver up to 3 cGy 
per study are used.
5.2.7
Quality Assurance
The institution will archive treatment prescription and verification images for later review by the 
study chair if requested. At least one port film or pretreatment alignment film per field along 
with the digital reconstructed radiographs (DRRs) from the treatment planning program or, 
alternatively, a simulation verification radiograph shall be acquired and kept for evaluation if 
requested except where geometrically impractical.
Cases which meet criteria as stated in Section 5.2.1 will be scored as per protocol. Cases which 
don’t will be scored as violations. Note that any deviations from the treatment target volumes 
and normal tissue constraints are considered planning deviations only and are not protocol 
deviations or violations. Protocol treatment may proceed in these cases with the approval of the 
Overall PI.
Acceptable dose heterogeneity will be as follows: The maximum dose volume of the PTV must 
not be shared by a normal critical structure. (Section 5.2.4). The maximum point dose to normal 
critical structures outside the PTV including the unspecified tissue should not exceed the 
prescription dose. The treating physician must carefully consider the tolerance dose/volume to 
each critical normal structure and unspecified tissue.
5.2.8
Dose Specifications / Technical Considerations: SBRT/Brachtherapy
SBRT considerations are the same as above.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
26
5.2.9
Radiation Quality Assurance Reviews
The study co-chair will review dosimetry for all plans upon completion of study.
5.2.10 Monitoring Radiation Adverse Events
All participants will be seen during radiation therapy by a radiation oncologist or nursing staff. 
Any observations with respect to symptoms / side effects will be recorded. Clinical discretion 
may be used in managing radiotherapy-related side effects. 
5.3
Pre-Treatment Evaluations
Following informed consent, all participants will undergo screening procedures within 28 days 
prior to registration to determine eligibility for study entry. Screening procedures include 
medical, surgical, cancer, and medication history; complete physical examination, including vital 
signs, height, and weight; Eastern Cooperative Oncology Group (ECOG) performance status; 
clinical laboratory assessments (complete blood count [CBC], serum chemistry, and urinalysis); 
and pregnancy test for women of childbearing potential.  Labs completed on Cycle 1 Day 1 
should re-meet eligibility prior to dosing. 
Patients must have a baseline tumor assessment to determine extent of disease and confirm 
presence of measurable disease. Please refer to Section 10.0 for a complete list of baseline study 
requirements. 
Initial tumor imaging at screening must be performed within 28 days prior to registration. Scans 
performed prior to the signing of the informed consent form as part of routine clinical 
management are acceptable for use as initial tumor imaging if they are of diagnostic quality and 
performed within 28 days prior to study registration.
Participants will undergo a biopsy at the time of fiducial placement if safely accessible by 
percutaneous approach. 
Blood samples will be collected pre-dose for correlative analysis. 
5.4
General Concomitant Medications 
Any medication the participant takes during the study other than the study drugs, including 
herbal and other nontraditional remedies, is considered a concomitant medication. All 
concomitant medications must be recorded in the CRF. 
Niraparib weakly induces cytochrome P450 (CYP)1A2 in vitro and is an insensitive substrate for 
P-glycoprotein (P-gp); therefore, investigators should be advised to use caution with drugs that 
are the sensitive substrates for CYP1A2 with a narrow therapeutic range, i.e. theophylline and 
tizanidine.
Patients are prohibited from receiving the following therapies during the treatment phase of this 
study: 

Systemic anticancer or biological therapy  

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
27

Immunotherapy or chemotherapy not specified in this protocol

Investigational agents other than niraparib and dostarlimab

Live vaccines within 30 days prior to the first dose of study drug and while participating 
in the study. Examples of live vaccines include, but are not limited to, the following: 
measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacille

Prophylactic cytokines (granulocyte colony-stimulating factor) should not be 
administered in the first cycle of the study but may be administered in subsequent cycles 
according to ASCO guidelines.

Systemic glucocorticoids for any purpose other than to manage symptoms of suspected 
immune-related adverse events. Note: use of inhaled steroids, local injection of steroids, 
and steroid eye drops are allowed. If medically deemed necessary (e.g. acute asthma or 
COPD exacerbation), investigators are allowed to use their judgment to treat patients 
with systemic steroids. In such cases, systemic steroids should be stopped at least 24 
hours prior to the next dose of dostarlimab.
5.5
Supportive Care Guidelines
Patients should receive appropriate supportive care measures as deemed necessary by the treating 
investigator, including but not limited to the items outlined below. Prophylactic cytokines (e.g. 
G-CSF) should be administered according to current ASCO guidelines after the first cycle.
Note: it may be necessary to perform additional procedures such as bronchoscopy, endoscopy, or 
skin photography as part of evaluation of the event. 
Supportive care should be provided at the discretion of the treating physician, but guidelines for 
treatment are as follows:
5.5.1
Pneumonitis: 

Treat with systemic corticosteroids, oral for Grade 2 (e.g., 0.5-1 mg/kg/day of prednisone 
or equivalent) and IV for Grade 3-4 (e.g., 1 to 2 mg/kg/day of prednisone or equivalent).

Administer additional anti-inflammatory measures, as needed.

Taper corticosteroids when symptoms improve to Grade 1 or less over no less  than 4 
weeks.

If Grade 2 and no improvement or worsening over 2 weeks, treat as Grade 3-4.  

Consider prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration.
5.5.2
Diarrhea/Colitis
Monitor carefully for signs and symptoms of enterocolitis (such as diarrhea, abdominal pain, 
blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs 
and ileus).

All participants who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids. If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion.

For Grade 2 diarrhea/colitis that persists > 3 days, administer oral corticosteroids (e.g., 
0.5-1.0 mg/kg/day of prednisone or equivalent). If symptoms persist or worsen with 
steroids, treat as Grade 3-4.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
28

For Grade 3 or 4 diarrhea/colitis that persists > 3 days, treat with IV steroids (e.g., 1 to 2 
mg/kg/day of prednisone or equivalent) followed by high-dose oral steroids.  The patient 
may also be treated with Infliximab.

Taper corticosteroids when symptoms improve to Grade 1 or less over no less than 4 
weeks.
5.5.3
Type 1 diabetes mellitus or ≥ Grade 3 hyperglycemia
For type I diabetes mellitus and for Grade 3-4 hyperglycemia associated with metabolic acidosis 
or ketonuria, insulin replacement therapy is required. 
5.5.4
Hypophysitis

Treat with systemic corticosteroids, oral for Grade 2 (e.g., 0.5-1 mg/kg/day of prednisone 
or equivalent) and IV for Grade 3-4 (e.g., 1 to 2 mg/kg/day of prednisone or equivalent).

Taper corticosteroids when symptoms improve to Grade 1 or less over no less than 4 
weeks.

Replacement of appropriate hormones may be required as the steroid dose is tapered.
5.5.5
Hyperthyroidism or Hypothyroidism
Thyroid disorders have been reported with other PD-1 inhibitors occurring at any time during 
treatment. Monitor participants for changes in thyroid function (at the start of treatment, 
periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs 
and symptoms of thyroid disorders.

Grade 2 HYPERthyroidism events

Consider non-selective beta-blockers (e.g., propranolol) as initial therapy. 

Grade 3-4 HYPERthyroidism

Treat with an initial dose of IV corticosteroids followed by oral 
corticosteroids (e.g., 0.5-1 mg/kg/day of prednisone or equivalent). Taper 
corticosteroids when symptoms improve to Grade 1 or less over no less than 
4 weeks. Replacement of appropriate hormones may be required as the steroid 
dose is tapered.

Grade 2-4 HYPOthyroidism

Thyroid hormone replacement therapy, with levothyroxine or liothyronine, is 
indicated per standard of care.
5.5.6
Hepatitis

Treat with systemic corticosteroids, oral for Grade 2 (initial dose of 1- 2 mg/kg/day of 
prednisone or equivalent) and IV for Grade 3-4 (1-2 mg/kg/day of prednisone or 
equivalent)

Taper corticosteroids when symptoms improve to Grade 1 or less over no less than 4 
weeks.
5.5.7
Renal Failure or Nephritis

Treat with systemic corticosteroids, oral for Grade 2 (initial dose of 0.5-1 mg/kg/day of 
prednisone or equivalent) and IV for Grade 3-4 (1-2 mg/kg/day of prednisone or 
equivalent). Taper corticosteroids when symptoms improve to Grade 1 or less over no 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
29
less than 4 weeks.
5.6
Criteria for Taking a Participant Off Protocol Therapy
Duration of therapy will depend on individual response, evidence of disease progression and 
tolerance. Patients are permitted  to stay on study beyond TIMC determined progression if they 
have not yet received radiation or their first set of protocol  scans. Due to expected delayed 
treatment response prior to radiation,  the decision to keep patients on trial past progression will 
be made by the treating physician. In the absence of treatment delays due to adverse event(s), 
treatment may continue until one of the following criteria applies:

Disease progression (exceptions defined above)

Intercurrent illness that prevents further administration of treatment including a 
diagnosis of MDS or AML

Participant becomes pregnant

Unacceptable adverse event(s)

Participant demonstrates an inability or unwillingness to comply with the medication 
regimen and/or documentation requirements

Participant decides to withdraw from the protocol therapy

General or specific changes in the participant's condition render the participant 
unacceptable for further treatment in the judgment of the treating investigator

Investigator, Sponsor, and/or GSK becomes aware of conditions or events that 
suggest a possible risk or hazard to participants if the clinical study continues

Hospice: Patients who transition into hospice care will be taken off active follow-up 
and followed for survival data if possible, including date of death. 
Participants will be removed from the protocol therapy when any of these criteria apply.  The 
reason for removal from protocol therapy, and the date the participant was removed, must be 
documented in the case report form (CRF). Alternative care options will be discussed with the 
participant.
When a participant is removed from protocol therapy and/or is off of the study, the relevant Off-
Treatment/Off-Study information will be updated in OnCore.
5.7
Duration of Follow Up
The first follow up visit or off treatment visit will be at least 30 days from the last dose of 
protocol therapy (+/- 7 days) or may coincide with the date of discontinuation of treatment (+/- 7 
days) if the date of discontinuation is greater than 37 days after the last dose. Patients will either 
be seen in clinic or called every 12 weeks for the first two years of follow-up and then at least 
every 6 months for years 3-5. 
Participants removed from protocol therapy for unacceptable adverse event(s) will be followed to 
ensure resolution or stabilization of the adverse event.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
30
5.8
Criteria for Taking a Participant Off Study
Participants will be removed from study and followed for survival (if applicable) when any of 
the following criteria apply:

Lost to follow-up

Withdrawal of consent for data submission

Death

Termination of the study

Hospice: Patients who transition into hospice care will be taken off active follow-up and 
followed for survival data if possible, including date of death.
The reason for taking a participant off study, and the date the participant was removed, must be 
documented in the case report form (CRF). In addition, the study team will ensure Off 
Treatment/Off Study information is updated in OnCore in accordance with DF/HCC policy 
REGIST-101.
For participants who are thought to be lost to follow-up, at least 3 documented attempts, 
including 1 via certified mail, should be made to contact the participant before the participant is 
deemed lost to follow-up.
6. DOSING DELAYS/DOSE MODIFICATIONS
Dose delays and modifications will be made as indicated below. The descriptions and grading 
scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.0 will be utilized for dose delays and dose modifications. A copy of the CTCAE 
version 5.0 can be downloaded from the CTEP website
 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. 
6.1
Radiation Dose Modifications 
Radiation dose modifications and delays will be determined at the discretion of the treating 
physician. 
6.2
Dostarlimab Dose Modifications
AEs (both non-serious and serious) associated with dostarlimab exposure may represent an 
immunologic etiology. These AEs may occur shortly after the first dose or several months after 
the last dose of treatment.
In general, dostarlimab must be withheld for drug-related Grade 3 toxicities, as well as for 
certain immune-related adverse events of interest (irAEIs), but may be resumed upon recovery 
to Grade ≤1; dostarlimab will be permanently discontinued for any drug-related Grade 4 AE. 
dostarlimab must be permanently discontinued for certain irAEIs as described in Table 2.  
The specific immune-related AEs typically observed with anti-PD-1 antibodies will be 
managed according to the guidelines summarized below. 
Immune-related Adverse Events of Interest and Guidelines for Management

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
31
Given the mechanism of action of dostarlimab, it is anticipated that activation of cellular immune 
system can be manifested as immune-related AEs. Based on available safety data from 
checkpoint inhibitors, treatment emergent adverse events (TEAEs) with the specific grades listed 
below were selected as immune-related adverse events of interest (irAEIs). The list of irAEIs 
may be updated upon emerging data.
Refer to Table 2 for details on the management of dostarlimab dose delays and discontinuation 
for specific irAEIs. Detailed guidance for the administration of rescue medications and 
supportive care are available below. For all irAEIs listed in Table 2, dostarlimab should be 
withheld until the patient is clinically and metabolically stable and AEs have resolved to Grade 
≤1. If systemic steroids are used as a part of irAEI management, the total dose of daily steroids 
should be equal to or less than 10mg prednisone at the time of resuming dostarlimab.
All treatment delays (including any missed doses) and discontinuations, and the reason for delays 
or discontinuation of dostarlimab, should be documented.
Table 2: Guidelines for Treatment of Immune-related Adverse Events of Interest
Toxicity
Withhold Treatment 
for AE Grade
Restarting Treatment/Discontinuation
Uveitis
Symptomatic any 
grade
Restart when toxicity resolves to Grade 0. For any 
recurrent uveitis or uveitis resistant to topical steroids, 
permanently discontinue treatment. 
2 to 3
Restart dosing when toxicity resolves to Grade 0 to 1.
Diarrhea/colitis
4
Permanently discontinue.
2
(AST or ALT > 3 and 
≤ 5 × ULN or total 
bilirubin > 1.5 and ≤ 3 
× ULN)
Restart dosing when toxicity resolves to Grade 0 to 1.
AST, ALT, or 
increased 
bilirubin
3 or 4 
(AST or ALT > 5 × 
ULN or total bilirubin 
> 3 × ULN)
Permanently discontinue (see exception below)a.
T1DM or 
hyperglycemia
3 or 4 hyperglycemia 
or T1DM (associated 
with metabolic acidosis 
or ketonuria)
Restart dosing in appropriately managed, clinically and 
metabolically stable patients, insulin replacement 
therapy is required.
Immune-related 
encephalitis
Any grade
Permanently discontinue.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
32
Toxicity
Withhold Treatment 
for AE Grade
Restarting Treatment/Discontinuation
Hypophysitis
2 to 4
For Grade 2 to 3 AEs, hold until hormonal therapy 
results in return to adequate levels by laboratory values 
and restart dosing when toxicity resolves to Grade 0 to 1. 
For recurrence or worsening of Grade ≥2 hypophysitis 
after corticosteroid taper has been completed and patient 
is on adequate hormone replacement therapy, 
permanently discontinue. For Grade 4 AEs, permanently 
discontinue.
2 to 3
Hold until hormonal therapy results in return to adequate 
levels by laboratory values and restart dosing when 
toxicity resolves to Grade 0 to 1. For recurrent or 
worsening ≥ 2 adrenal insufficiency while adequate 
hormonal replacement is continuing, permanently 
discontinue study drug. 
Adrenal 
Insufficiency
4
Permanently discontinue.
3
Hold until hormonal therapy results return to adequate 
levels by laboratory values and restart dosing when 
toxicity resolves to Grade 0 to 1. 
Hypo- and 
Hyperthyroidism
4
Permanently discontinue.
2b
Restart dosing when toxicity resolves to Grade 0 to 1.
Infusion-related 
reaction
3 or 4
Permanently discontinue.
2
Restart dosing when toxicity resolves to Grade 0 to 1. If 
Grade 2 recurs, permanently discontinue.
Pneumonitis
3 or 4
Permanently discontinue.
3
Restart dosing when toxicity resolves to Grade 0 to 1.
Rash
4
Permanently discontinue.
2
Restart dosing when toxicity resolves to Grade 0 to 1.
Renal failure or 
nephritis
3 or 4
Permanently discontinue.
Recurrence of 
AEs after 
resolution to 
Grade ≤1
3 or 4
Permanently discontinue.
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; T1DM = 
type 1 diabetes mellitus; ULN = upper limit of normal.
a For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by 
≥50% relative to baseline and lasts for at least 1 week, then study treatment should be discontinued.
b Upon resolution within 1 hour of stopping drug infusion, the infusion may be restarted at 50% of the original 
infusion rate (e.g., from 100 to 50 mL/h). Otherwise, study treatment will be withheld until symptoms resolve, and 
the patient should be pre-medicated for the next scheduled dose.
Rescue Medications and Supportive Care Guidelines

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
33
During treatment with dostarlimab, patients should receive appropriate supportive care measures 
for AEs as deemed necessary by the treating Investigator, including but not limited to the items 
outlined below. Prophylactic cytokines (eg, GCSF) should be administered according to current 
ASCO guidelines. 
Note: It may be necessary to perform additional procedures such as bronchoscopy, endoscopy, or 
skin photography as part of the evaluation of the AE. Specific detailed management guidance 
from ASCO (2018), ESMO (2018) and NCCN (2019)  for immune-mediated AE are provided in 
the weblink by Association of Community Cancer Centers. Investigators should follow these 
recommendations for management of the following events:

Uveitis

Pneumonitis

Diarrhea/colitis 

Type I diabetes and grade 3 and 4 hyperglycemia

Hypophysitis

Adrenal insufficiency

Hyperthyroidism and hypothyroidism

Hepatitis 

Renal failure or nephritis
Management of Infusion-Related Reactions 
Signs and symptoms usually develop during or shortly after drug infusion and generally resolve 
completely within 24 hours of completion of infusion.  Table 3 shows treatment guidelines for 
patients who experience an infusion-related reaction associated with administration of 
dostarlimab.
Table 3: Dostarlimab Infusion Reaction Treatment Guidelines
CTCAE Grade
Treatment
Premedication at Subsequent 
Dosing
Grade 1
Mild reaction; infusion 
interruption not 
indicated; intervention 
not indicated 
Increase monitoring of vital signs as 
medically indicated until the patient is 
deemed medically stable in the opinion of 
the Investigator.
None.
Grade 2
Requires infusion 
interruption but 
responds promptly to 
symptomatic treatment 
(e.g., antihistamines, 
NSAIDs, narcotics, or 
IV fluids); prophylactic 
medications indicated 
for ≤24 h
Stop infusion and monitor symptoms.
Additional appropriate medical therapy 
may include but is not limited to: 

IV fluids

Antihistamines

NSAIDs

Acetaminophen
Patient may be pre-medicated 
1.5 h (±30 min) prior to 
infusion of dostarlimab with: 

Diphenhydramine 50 mg 
PO (or equivalent dose 
of antihistamine)

Acetaminophen 500 to 
1000 mg PO (or 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
34

Narcotics
Increase monitoring of vital signs as 
medically indicated until the patient is 
deemed medically stable in the opinion of 
the Investigator.
If symptoms resolve within 1 hour of 
stopping drug infusion, the infusion may 
be restarted at 50% of the original 
infusion rate (e.g., from 100 mL/h to 50 
mL/h). Otherwise, dosing will be 
withheld until symptoms resolve, and the 
patient should be pre-medicated for the 
next scheduled dose.
Patients who develop Grade 2 toxicity 
despite adequate premedication should be 
permanently discontinued from further 
study treatment administration.
equivalent dose of 
antipyretic)
Grade 3:
Prolonged (ie, not 
rapidly responsive to 
symptomatic 
medication and/or brief 
interruption of 
infusion); recurrence of 
symptoms following 
initial improvement; 
hospitalization 
indicated for other 
clinical sequelae (e.g., 
renal impairment, 
pulmonary infiltrates)
Grade 4:
Life-threatening; 
pressor or ventilatory 
support indicated 
Stop Infusion.
Additional appropriate medical therapy 
may include but is not limited to: 

IV fluids

Antihistamines

NSAIDs

Acetaminophen

Narcotics

Oxygen

Pressors

Corticosteroids

Epinephrine
Increase monitoring of vital signs as 
medically indicated until the patient is 
deemed medically stable in the opinion of 
the Investigator.
Hospitalization may be indicated.
Patient is permanently discontinued 
from further study treatment 
administration.
No subsequent dosing.
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; IV = intravenous; NSAID = 
nonsteroidal anti-inflammatory drug; PO = oral.
Note: Appropriate resuscitation equipment should be available in the room and a physician readily available during 
the period of study treatment administration.
6.3
Niraparib Dose Modifications
Dose interruption and/or modification of niraparib may be implemented due to nonhematologic 
or hematologic toxicities per the Investigator’s judgement after Cycle 1. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
35
Treatment must be interrupted for any nonhematologic Common Terminology Criteria for 
Adverse Events (CTCAE) Grade 3 or 4 AE that the Investigator considers to be related to 
administration of niraparib (Table 3). If the nonhematologic toxicity is appropriately resolved to 
baseline or Grade ≤1 within 4 weeks (28 days) of the dose interruption period, the patient may 
restart treatment with niraparib but with a dose level reduction if prophylaxis is not considered 
feasible (see Table 5). If the event recurs at similar or worse grade, treatment should be   
interrupted again and, upon resolution, a further dose reduction must be made according to Table 
4. 
If the toxicity requiring dose interruption has not resolved completely or to CTCAE Grade 1 
during the maximum 4-week (28-day) dose interruption period, and/or the patient has already 
undergone a dose reduction to a minimum dose of 100 mg QD, the patient must permanently 
discontinue treatment with niraparib.
The dose interruption and modification criteria for niraparib for hematologic parameters will be 
based on blood counts and are outlined in Table 6. If the hematologic toxicity has not recovered 
to the specified levels within 4 weeks (28 days) of the dose interruption period, the patient must 
permanently discontinue treatment with niraparib.
For major surgery while on study treatment, up to 4 weeks (28 days) of study treatment 
interruption is allowed. For patients whose initial dose is 3 capsules daily (300 mg/day), dose 
reductions to 2 capsules daily (200 mg/day) and subsequently to 1 capsule daily (100 mg/day) 
will be allowed. No further dose reduction will be allowed. 
For patients whose initial dose is 2 capsules (200 mg/day), dose reduction to 1 capsule once daily 
(100 mg/day) will be allowed. No further dose reduction will be allowed.
Table 4:
Recommended Dose Modifications for Adverse Reactions
Dose level
Initial Dose: 3 capsules per day
Initial Dose: 2 capsules per day
Starting dose
3 capsules once daily (300 mg/day) 
2 capsules once daily (200 mg/day) 
First dose 
reduction
2 capsules once daily (200 mg/day) 
1 capsule once daily (100 mg/day)
Second dose 
reduction
1 capsule once daily (100 mg/day)
NA
Table 5: Niraparib Dose Modifications for Nonhematologic Adverse Reactions
Abnormality
Intervention
Non-hematologic CTCAE ≥ Grade 3 adverse 
reaction where prophylaxis is not considered 
feasible or adverse reaction persists despite 
treatment
Withhold niraparib for a maximum of 28 days or until 
resolution of adverse reaction.
Resume niraparib at a reduced dose. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
36
Abnormality
Intervention
CTCAE ≥ Grade 3 treatment-related adverse 
reaction lasting more than 28 days while 
patient is administered niraparib 100 mg/day
Discontinue niraparib.
Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events.
Hypertension: Hypertension, including hypertensive crisis, has been reported with the use of 
niraparib. Pre-existing hypertension should be adequately controlled before starting niraparib 
treatment. Blood pressure and heart rate should be monitored at least weekly for the first 2 
months, then monthly for the first year and periodically thereafter during treatment with 
niraparib. 
Hypertension should be medically managed with antihypertensive medicinal products as well as 
adjustment of the niraparib dose, if necessary. In the clinical program, blood pressure 
measurements were obtained on Day 1 of each 28 day cycle while the patient remained on 
niraparib. In most cases, hypertension was controlled adequately using standard antihypertensive 
treatment with or without niraparib dose adjustment. Niraparib should be discontinued in case of 
hypertensive crisis or if medically significant hypertension cannot be adequately controlled with 
antihypertensive therapy.
Posterior Reversible Encephalopathy Syndrome (PRES): There have been rare reports 
(0.09% of clinical trial patients) of niraparib-treated patients developing signs and symptoms that 
are consistent with Posterior Reversible Encephalopathy Syndrome (PRES). PRES is a rare 
neurologic disorder that can present with the following signs and symptoms including seizures, 
headache, altered mental status, visual disturbance, or cortical blindness, with or without 
associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, 
preferably magnetic resonance imaging (MRI). In patients developing PRES, treatment of 
specific symptoms including control of hypertension is recommended, along with 
discontinuation of niraparib. The safety of reinstating niraparib therapy in patients previously 
experiencing PRES is not known.
Table 6: Niraparib Dose Modifications for Hematologic Toxicity

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
37
Laboratory Abnormality
Intervention
Monitor complete blood counts weekly for the first two cycles, then at the start of each following cycle 
for the next 11 months of treatment, and periodically after this time.
First occurrence:
Withhold niraparib for a maximum of 28 days and monitor blood 
counts weekly until platelet counts return to ≥100,000/μL.
Resume niraparib at same or reduced dose per Table 3.
If platelet count is < 75,000/μL, resume niraparib at a reduced 
dose per Table 3.
Platelet count < 100,000/μL
Second occurrence:
Withhold niraparib for a maximum of 28 days and monitor blood 
counts weekly until platelet counts return to ≥100,000/μL.
Resume niraparib at a reduced dose per Table 3. 
Discontinue niraparib if the platelet count has not returned to 
acceptable levels within 28 days of the dose interruption period, 
or if the patient has already undergone dose reduction to 100 mg 
QD.
Neutrophil count < 1,000/μL
Withhold niraparib for a maximum of 28 days and monitor blood 
counts until neutrophil counts return to ≥1,500/μL. 
Resume niraparib at a reduced dose per Table3.
Discontinue niraparib if neutrophil level has not returned to 
acceptable levels within 28 days of the dose interruption period, 
or if the patient has already undergone maximum dose reductions 
per Table 3.
Hemoglobin ≤ 8 g/dL
Withhold niraparib for a maximum of 28 days and monitor blood 
counts until hemoglobin returns to ≥9 g/dL. 
Resume niraparib at a reduced dose per Table 3.
Discontinue niraparib if hemoglobin has not returned to 
acceptable levels within 28 days of the dose interruption period, 
or if the patient has already undergone maximum dose reductions 
per Table 3.
Hematologic adverse reaction 
requiring transfusion
For patients with platelet count ≤10,000/μL, platelet transfusion 
should be considered. If there are other risk factors such as 
co-administration of anticoagulation or antiplatelet drugs, 
consider interrupting these drugs and/or transfusion at a higher 
platelet count.
Resume niraparib at a reduced dose per Table 3.  
Confirmed diagnosis of MDS or 
AML
Permanently discontinue niraparib.
Abbreviation: AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; QD = once daily. 
Thrombocytopenia: In the case of thrombocytopenia, following the first occurrence, resumption 
of therapy may occur at the same dose or 1 dose level lower when the hematologic toxicity has 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
38
resolved. Subsequent occurrences should trigger dose reduction upon resumption of therapy. If 
the platelet count has not reverted within 28 days of interruption to ≥100,000/μL, then study 
treatment should be discontinued.
General Hematologic Toxicity: If dose interruption and/or modification is required at any point 
during study treatment because of hematologic toxicity, weekly blood draws for complete blood 
count (CBC) will be monitored until the AE resolves to the specified blood count levels. To 
ensure the safety of the new dose, weekly blood draws for CBC will be required for an additional 
4 weeks after the AE has resolved, after which monitoring every 4 weeks may resume. CBC 
monitoring will continue every 4 weeks (ie, monthly) for the next 11 months of treatment, and 
periodically after this time.
Any patient requiring transfusion of platelets or red blood cells (≥1 unit) must undergo a dose 
reduction upon recovery if study treatment is resumed.
Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML): If a diagnosis of 
MDS/AML is confirmed by a hematologist, the patient must permanently discontinue study 
treatment.
7. EXPECTED TOXICITIES AND TOXICITY REPORTING
Participants will be monitored for adverse events and serious adverse events from the first dose 
of investigational agent through 30 days after the last dose of any study drug. All adverse events 
experienced by participants will be documented. Toxicities will be closely followed. Start and 
stop dates will be documented, as will changes in grade over time.
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of reported and/or potential AEs (Section 7.1) and the characteristics of an 
observed AE (Section 7.2) will determine whether the event requires expedited reporting in 
addition to routine reporting.
7.1
Expected Toxicities
7.1.1
Adverse Events List for  dostarlimab 
Based on observed side effects from approved drugs of the same class/type (anti-PD-1 
antibodies), the most common side effects of  dostarlimab are (>20%) are:

Fatigue

Anemia 

Nausea

Decreased appetite

Arthralgia

 Diarrhea

Pruritus

Vomiting

Increase in the liver enzyme aspartate aminotransferase (AST)

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
39

Asthenia

Myalgia

Rash

Creatinine increase

Hhypokalemia

Hypothyroidism

Muscular weakness
Side effects that were experienced by <1 include the following: 

Pneumonitis

Autoimmune hemolytic anemia
Side effects that were experienced by patients taking anti-PD-1 antibodies:  

Inflammation of the skin

Inflammation of the bowels/gut

Inflammation of the lungs

Inflammation of the liver 

Inflammation of the pituitary gland 

Too much/too little thyroid hormone

Inflammation of the kidney

Inflammation of the muscles

Inflammation of the pancreas

Inflammation of the brain
7.1.2
Adverse Event List for Niraparib
Side effects that were experienced by 10% or more of patients who took niraparib as a single 
drug therapy, include the following: 

Anemia

Thrombocytopenia

Neutropenia

Constipation

Nausea

Vomiting

Decreased appetite

Headache

Fatigue

Abdominal pain  

Dyspepsia

Cough

Urinary tract infection

Diarrhea

Dyspnea

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
40

Nasopharyngitis

Insomnia

Dysgeusia

Palpitations  

Arthralgia

Back pain

Hypertension

Leukopenia

Dizziness

Asthenia
Side effects that were experienced by 1% or more but fewer than 10% of patients who took 
niraparib as a single agent include the following: 

Neutropenic infection

Photosensitivity 

Dysgeusia

Conjunctivitis

Hypokalemia

Tachycardia

Dry mouth

Anxiety

Nose bleeds

Rash

Muscle pain

Mucositis/stomatitis

Increases in liver enzyme

Blood creatinine increase

Weight loss

Depression

Bronchitis

Peripheral edema
Serious side effects that resulted in the need for medical care: 
•
Decrease in platelets 
•
Decrease in red blood cells 
•
Decrease in neutrophil cells
•
Hypertension  
•
Posterior Reversible Encephalopathy Syndrome (PRES)
Because niraparib is a PARP inhibitor, there is also a potential risk for developing acute myeloid 
leukemia and/or myelodysplastic syndrome (MDS). 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
41
7.1.3
Adverse Event List for Radiation Therapy
Likely (more than a 20% chance that this will happen)

Abdominal Pain

Nausea

Vomiting

Weight loss

Fatigue

Skin irritation and/or reddening

Alopecia

Increased risk of infection, including pneumonia

Decreased blood counts, which may cause shortness of breath, dizziness, and fatigue

Elevated liver function tests, which may cause fatigue and jaundice (yellowing of the skin 
and eyes)

Low platelet count, which may cause an increase in chance of bleeding (nosebleeds, bruising, 
stroke, and/or digestive system bleeding), and patient may need a platelet transfusion
Occasional (Between a 3-20% chance that this will happen)

Esophagitis

Pneumonitis

Liver damage

Skin damage

Slow wound healing
Rare but Serious (Less than a 3% chance that this will happen)

Chest wall fracture

GI bleed

Bowel perforation

Secondary cancer
7.2
Adverse Event Characteristics
The descriptions and grading scales found in the revised NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting. All appropriate treatment 
areas should have access to a copy of the CTCAE version 5.0.  A copy of the CTCAE version 
5.0 can be downloaded from the CTEP web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
An AE may also be defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily have to 
have a causal relationship with this treatment. An AE can therefore be any unfavorable and 
unintended sign (including a clinically significant abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of study treatment, whether or not 
considered related to the study treatment. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
42
AEs may include the onset of new illness and the exacerbation of pre-existing medical 
conditions. An AE can include an undesirable medical condition occurring any time after the 
first study treatment has been administered.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention or 
a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be 
reported regardless of sequelae
Adverse events that are listed above in section 7.1 are subject to expedited reporting only if the 
adverse event varies in nature, intensity, or frequency from the expected toxicity information that 
is provided.
Attribution of adverse events will be as follows: 

Definite – The AE is clearly related to the study treatment.

Probable – The AE is likely related to the study treatment.

Possible – The AE may be related to the study treatment.

Unlikely – The AE is doubtfully related to the study treatment.

Unrelated – The AE is clearly NOT related to the study treatment.
When reporting to GSK, attribution must be reported as either “related” or “not related’.
An adverse event is considered serious if it results in ANY of the following outcomes:

Death

A life-threatening adverse event 

An adverse event that results in inpatient hospitalization or prolongation of existing 
hospitalization for ≥ 24 hours 

A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 

A congenital anomaly/birth defect. 

Important Medical Events (IME) that may not result in death, be life threatening, or 
require hospitalization may be considered serious when, based upon medical judgment, 
they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. (FDA, 21 CFR 
312.32; ICH E2A and ICH E6).
*Exception: Preplanned (at time of informed consent) hospitalization for elective procedures, for 
protocol compliance or social reasons, or for observation will not be considered criteria for an 
SAE. The reason for the planned hospitalization should be documented. Complications 
experienced during these hospitalizations must be reported as SAEs if hospitalization is 
prolonged due to AE, or if the complication meets other serious criteria).
An Adverse Event of Special Interest is defined as any AE (serious or non-serious) that is of 
scientific and medical concern specific to the study treatment, for which ongoing monitoring and 
rapid communication to the Sponsor Institution and to GSK is required. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
43
Adverse Events of Special Interest (AESI) for niraparib include the following [note: there are no 
AESI identified for dostarlimab]:

Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Secondary cancers (new malignancies [other than MDS or AML])
Report serious AESI on SAE Report Forms, as follows:

MDS and AML along with other secondary cancers should be reported to the Sponsor 
Institution and to GSK upon awareness for any patient who has received niraparib 
(regardless of the timeframe since the last dose).  
Assessment of Adverse Events 
Each AE will be assessed by the investigator for severity and for a causal relationship with the 
study treatment as outlined below.
Severity Assessment 
All AEs will be assessed by the Investigator for severity according to Common Terminology 
Criteria for Adverse Events (CTCAE) v5.0: 27 November 2017; National Institutes of Health 
(NIH), National Cancer Institute (NCI). The CTCAE severity grades 1 through 5 provide unique 
clinical descriptions of severity of each adverse event. The CTCAE v5.0 is available on the 
NCI/NIH website.
Please note that there is a distinction between serious and severe AEs: Severity is a measure of 
intensity whereas seriousness is defined by the criteria above. For example, a mild degree of 
gastrointestinal bleeding requiring an overnight hospitalization for monitoring purposes may be 
considered an SAE but is not necessarily severe. 
7.3
 Expedited Adverse Event Reporting 
Investigators must report to the Overall PI any serious adverse event (SAE) or Adverse Event of 
Special Interest (AESI) that occurs after the initial dose of study treatment, during treatment, or 
within 30 days of the last dose of treatment on the local institutional SAE form. 
Investigative sites within DF/HCC will report AEs directly to the DFCI Office for Human 
Research Studies (OHRS) per the DFCI IRB reporting policy. 
DF/HCC Reportable AEs
Attribution
Gr. 2 & 3 AE
Expected
Gr. 2 & 3 AE 
Unexpected
Gr. 4 AE Expected
Gr. 4 AE
Unexpected
Gr. 5 AE 
Expected or 
Unexpected
Unrelated
Unlikely
Not required
Not required
5 calendar days#
5 calendar days
24 hours*
Possible
Probable
Definite
Not required
5 calendar days
5 calendar days#
5 calendar days
24 hours*
* For participants enrolled and actively participating in the study or for AEs occurring within 30 days of the last 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
44
intervention, the AE should be reported within 1 business day of learning of the event.
Relationship to Study Drug 
The Investigator must provide a causality assessment regarding the relationship of the event with 
the study drug for all AEs.  One of the following categories should be selected based on medical 
judgment, considering all contributing factors:

Related: A causal relationship between the medicinal product and AE is a reasonable 
possibility. For example, the occurrence of the AE cannot be explained by other causative 
factors. The AE, however, can be explained by pharmacological effect of the medicinal 
product such as a similar event having been reported previously, alteration of the dose 
effect, or the timing or seriousness of the AE, etc. Positive rechallenge/dechallenge is 
supportive.

Not Related: A causal relationship between the medicinal product AE is not a reasonable 
possibility: there is no temporal relationship between the medicinal product and event, or 
an alternative etiology is more reasonable
7.4
Collection and Recording of Adverse Events
AEs may be volunteered spontaneously by the study patient, or discovered by the study staff during 
physical examinations or by asking an open, nonleading question such as, “How have you been 
feeling since your last study visit?” The Investigator will document the nature of AE, date of onset 
of the AE (and time, if known), date of outcome of the AE (and time, if known), severity of the 
AE, action taken with study drug as a result of the AE, assessment of the seriousness of the AE, 
and assessment of the causal relationship of the AE to study drug and/or study procedure.
AEs, including laboratory abnormalities that are assessed as clinically significant or require 
intervention, should be described using a diagnosis whenever possible, rather than individual 
underlying signs and symptoms. When a clear diagnosis cannot be identified, each sign or 
symptom should be recorded as a separate AE.
All SAEs will be collected (within 24 hours of notification of the event) by the investigator to the 
sponsor from first day of study treatment, and must be throughout the study and for at least 30 
days after the last dose of protocol therapy.
SAEs considered by the Investigator to be related to study medication will be reported regardless 
of the timeframe from last dose of protocol therapy.
All AEs will be documented for each patient from the signing of the ICF, and must be throughout 
the study and for at least 30 days after the last dose of protocol therapy.
Concomitant illnesses that existed before entry into the study are to be documented as medical 
history and will not be considered AEs unless the illness worsens after initiating protocol therapy. 
Disease progression is an efficacy criterion and is therefore not considered an AE or SAE (even if 
fatal). Disease progression should be documented but not reported as an SAE. If AEs/SAEs occur 
in relation to disease progression that are not consistent with the natural progression of the patient’s 
disease, these AEs/SAEs must be reported per AE/SAE reporting requirements.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
45
7.5
Follow-Up of Adverse Events
All AEs experienced by a patient, regardless of the suspected causality, will be monitored until the 
AE or SAE has resolved, until any abnormal laboratory values have returned to baseline or normal 
levels, until stabilized with a satisfactory explanation for the changes observed, until the patient is 
lost to follow-up, or until the patient has died.
7.6
Reporting to GSK 
SAEs (including by default serious AESI)
The Sponsor Institution must report all SAEs and all follow up information to GSK on a GSK-
specific SAE Report Form or MedWatch form with accompanying coversheet or MedWatch 
form within 24 hours of becoming aware of the initial event or clinically significant follow-up 
information. 
The Sponsor must provide a causality assessment and must sign and date all SAE Report Forms.
If supporting documentation is included in the submission to GSK (e.g., hospital reports, 
consultant reports, death certificates, autopsy reports, etc.), please redact any patient identifiers 
(including Medical Record number).
Pregnancies
The Sponsor has the responsibility to monitor the outcome of all pregnancies reported during the 
Investigator Sponsored Trial.
The Sponsor must report all pregnancies associated with GSK product including follow up 
outcomes to GSK within 24 hours of awareness. 
Each pregnancy must be reported on an Initial Pregnancy Report Form within 24 hours of 
becoming aware of the pregnancy. Pregnancy is not an AE, and therefore does not need to be 
reported as an AE unless there is a suspicion that the study drug may have interfered with the 
effectiveness of a contraceptive medication. 
An elective abortion without complications should not be regarded as an AE, however, it should 
be reported as the outcome to the pregnancy on the Pregnancy Outcome Report Form. 
Therapeutic abortions should be reported as a treatment procedure; the reason for the therapeutic 
abortion should be reported on the Pregnancy Outcome Report Form and as an AE. 
Hospitalization for normal delivery of a healthy newborn should not be considered an SAE.
Any SAE that occurs during pregnancy must be recorded on the Pregnancy Outcome Report 
Form, reported as an SAE on the SAE Report Form (e.g., maternal serious complications, 
therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death, congenital anomaly, birth 
defect) and reported to the Sponsor Institution and GSK within 24 hours. Hospitalization for 
normal delivery of a healthy newborn should not be considered an SAE. 
Reporting Contact Information

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
46
GSK SAE and Pregnancy Reporting Information
 Email: OAX37649@gsk.com
Fax: +44(0) 208754 7822
Reporting Product Complaints for GSK Products
Any written, electronic or oral communication that alleges dissatisfaction related to 
manufactured clinical drug product with regards to its manufacturing, testing, labeling, 
packaging, or shipping, must be reported by the Sponsor Institution or qualified designee to GSK 
QA (Email: tesaro.qa@gsk.com) within 1 working day of first becoming aware of the possible 
defect.  The product and packaging components in question, if available, must be quarantined in 
a secure area under specified storage conditions until it is determined whether the product is 
required to be returned for investigation of the defect.  If the product complaint is associated with 
an SAE, the SAE must be reported separately in accordance with the protocol, and the SAE 
report should mention the product quality complaint.
Suspected Unexpected Serious Adverse Reactions (SUSARs) 
Per regulatory requirements, if an event is assessed by the Sponsor as a Serious Unexpected 
Adverse Reaction (SUSAR), it is the responsibility of the Sponsor to submit the SUSAR to 
Regulatory Authorities according to applicable regulations.
In addition, the SUSAR will be distributed to the Investigators/sites utilizing a Council for 
International Organizations of Medical Sciences (CIOMS) report form, or the MedWatch 3500A 
form). The Investigator/site will submit a copy of the report to their respective Institutional 
Review Board (IRB) or Independent Ethics Committee (IEC) and GSK per the governing 
institutional requirements and in compliance with local laws and guidelines.
7.7
Reporting to the Food and Drug Administration (FDA)
The Overall PI, as study sponsor, will be responsible for all communications with the FDA. The 
Overall PI will report to the FDA, regardless of the site of occurrence, any serious adverse event 
that meets the FDA’s criteria for expedited reporting following the reporting requirements and 
timelines set by the FDA.
In addition, the SUSAR will be distributed to the Investigators/sites utilizing a Council for 
International Organizations of Medical Sciences (CIOMS) report form, or the MedWatch 3500A 
form). The Investigator/site will submit a copy of the report to their respective Institutional 
Review Board (IRB) or Independent Ethics Committee (IEC) and GSK per the governing 
institutional requirements and in compliance with local laws and guidelines.
7.8
Reporting to Hospital Risk Management

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
47
Participating investigators will report to their local Risk Management office any participant 
safety reports, sentinel events or unanticipated problems that require reporting per institutional 
policy. 
7.9
Routine Adverse Event Reporting
All Adverse Events must be reported in routine study data submissions to the Overall PI on the 
toxicity case report forms.  AEs reported through expedited processes (e.g., reported to the IRB, 
FDA, etc.) must also be reported in routine study data submissions.
8. PHARMACEUTICAL INFORMATION
8.1
Dostarlimab
8.1.1
Description
Dostarlimab is an IgG4 antibody.
8.1.2
Form
Dostarlimab will be supplied as a solution in vials containing 500 mg (50 mg/mL, respectively). 
Dostarlimab drug product is a sterile solution, essentially free from visible particles, supplied as 
a single use vial for intravenous administration. The solution is clear and colorless. The drug 
product is formulated in 25 mM citrate, 100 mM arginine, 31 mM sodium chloride, 0.02% 
polysorbate 80, pH 6. The  dostarlimab 500 mg has a protein concentration of 50 mg/ml with a 
deliverable volume of 10 mL.
8.1.3
Packaging, Labeling, and Storage
Dostarlimab for injection is supplied in vials containing 500 mg at a concentration of 50 mg/mL. 
The label text of the study treatment will comply with Good Manufacturing Practice and national 
legislation to meet the requirements of the participating countries. The study treatment will be 
open-label and non-patient-specific.
All study treatment supplies must be stored in accordance with the instructions and storage and 
handling guidelines. Until dispensed or administered to the patients, the study treatment will be 
stored in a securely locked area, accessible to authorized personnel only. Please see the Storage 
and Handeling Guidelines for further instructions on storing and hadeling Dostarlimab.
8.1.4
Availability
Dostarlimab is provided by GSK.  
The medication provided for this study is to be used only as indicated in this protocol and only 
for the participants entered in this study. 
Additional details can be found in the Storage and Handling Guidelines. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
48
8.1.5
Preparation
Infusions must be prepared aseptically by the pharmacist or designee. 
Dostarlimab must be diluted in Dextrose 5%(D5W) or Glucose 5% (G5W) in Sterile Water for 
Infusion only. Do not use filter needles during the preparation of  dostarlimab. Dostarlimab 
solution must not be added into airspace contained within the infusion bag. The final infusion 
bag/ syringe must not be shaken. 
The maximum infusion volume is 250mL plus overfill. 
8.1.6
Administration
The infusion should be administered using an intravenous infusion pump.  dostarlimab should 
not be infused in the same intravenous line with other products. A 0.2 or 0.22 micron, low-
protein binding, in-line filter should be used during administration of  dostarlimab. Dostarlimab 
will be administered using a planned 30-minute IV infusion (with a -5 minute and +15-minute 
window permitted). Authorized medical personnel will be responsible for the administration of 
medication throughout the study. Placement of an indwelling intravenous catheter for 
administration of infusions will be at the discretion of the Investigator. 
The infusion line should be primed with D5W or G5W or the infusion solution of  dostarlimab. 
The line should be primed via gravity to minimize air bubbles within the infusion line. 
At the end of the infusion, a D5W or G5W infusion bag should be hung to flush the line. The 
volume of D5W or G5W flushed through the line should be (at minimum) consistent with the 
volume of drug that is held with the line. This will ensure that the entire dose has been infused. 
The flush should be administered using the same final rate. Do not increase the infusion rate 
while flushing the line. 
8.1.7
Accountability
The Investigator or designee is responsible for maintaining accurate dispensing records of the 
study treatments throughout the clinical study.  Dostarlimab 
Dispensation and accountability records will be maintained. The pharmacist will dispense study 
treatment for each patient according to the protocol.
8.1.8
Destruction and Return
Unused  dostarlimab may be destroyed on site per standard procedure. 
8.2
Niraparib
8.2.1
Description
Niraparib ([3S]-3-[4- phenyl] piperidine [tosylate monohydrate salt]) is an orally available, 
potent, highly selective PARP1 and PARP2 inhibitor. The excipients for niraparib are lactose 
monohydrate and magnesium stearate. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
49
8.2.2
Form
Niraparib will be supplied as 100mg capsules for oral administration.
8.2.3
Storage and Stability
Niraparib will be stored at room temperature; 15oC – 30oC. It should not be refrigerated or 
frozen. Until dispensed to the participants, Niraparib supplies must be stored in a securely locked 
area, accessible to authorized personnel only.
8.2.4
Administration
Participants will be instructed to take study drug at approximately the same time each day. 
Participants must swallow capsules whole; they should not be opened, crushed or chewed. 
Niraparib may be taken with or without food. Niraparib will be dispensed to participants at the 
start of each 21-day cycle for the first 4 cycles.  Beginning at cycle 5, niraparib will be dispensed 
to participants on day 1 and day 22 of each 42-day cycle. Missed or vomited doses should not be 
made up. 
8.2.5
Availability
Niraparib is provided by GSK.  
The medication provided for this study is to be used only as indicated in this protocol and only 
for the participants entered in this study. 
Additional details can be found in the Storage and Handling Guidelines.
8.2.6
Accountability
The Investigator or designee is responsible for maintaining accurate dispensing records of the 
study treatments throughout the clinical study. Study drug accountability should be maintained 
by each site based on the capsules dispensed versus returned to the clinic at each visit and the 
number of days since the last visit. 
8.2.7
Destruction and Return
The investigational site is responsible for destruction of study drug according to local 
regulations. Both the unused and expired study drug must be destroyed according to local 
regulations and procedures, and a copy of the destruction form must be filed in the study binder.
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES
Serial blood = for cTDNA, CTC, flow cytometry, TCR repertoire, and ELISA
Tissue = DNA seq (Whole exome or genome), bulk and single-cell RNA seq, multiplex 
immunofluorescence, IHC, single cell RNA seq;TCR sequencing
9.1
Analysis for Repeat RNA Expression, DNA Damage Response, and 
Immune Infiltrates
We will analyze repeat RNA markers to predict response to DNA damaging agents and 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
50
activation of innate immune response. A total of 6 unstained slides of 5-micron thickness are 
requested for analysis. We have developed a RNA-ISH assay applicable to FFPE sectioned slides 
for repeat non-coding RNAs including HSATII. The assay has been automated but is not CLIA 
certified at this time. Given this early trial, we will assess this HSATII RNA-ISH and other 
repeats (TERRA, LINE1, HERVH) for exploratory biomarker development. In addition, we have 
found that these markers correlate to specific immune infiltrates. Notably, we have developed a 
combined RNA-ISH and immunohistochemistry, which has revealed a correlation of repeats 
with FOXP3 T-reg cell, CD163 macrophages, and CD8 T-cells.
As a complementary assay, we have developed computational pipelines to evaluate repeat RNAs 
using both standard Illumina RNA-seq as well as single molecule RNA-seq with the SeqLL 
platform. If available, we will perform RNA-seq on pretreatment and on treatment fresh frozen 
biopsies from patients on trial. RNA-seq will be done to quantify repeat RNAs, correlate to 
immune markers by RNA expression profiles, and correlate to DNA damage response genes.
Where available, we will additionally use 1-2 fresh cores for single-cell RNA-sequencing studies 
to further characterize immune cell subsets and cell states at high resolution. We have a well 
validated platform for performing single-cell transcriptomics. In brief, fresh biopsy cores will be 
immediately processed to create single cell suspensions for single cell RNAseq and TCR 
sequencing that will be performed by the Hacohen Lab at MGH and the Broad Institute . TCR 
sequencing will characterize the tumor infiltrating lymphocyte TCR repertoire over time. Single 
cell RNAseq will enable the study of gene programs at a single cell level. This will clarify the 
roles of various cell types within the tumor as well as the heterogeneity within those cell types.
In addition, participants will have the option to participate in DNA sequencing (targeted exome, 
whole exome, or whole genome) to assess effects of DNA damaging agents by quantifying total 
mutational burden, copy number variation, and chromosomal rearrangements.  This optional 
testing will be done at the MGH Cancer Center or be evaluated by a third party (Foundation 
Medicine, Cambridge, MA).
In order to perform the RNA-ISH assay, we will obtain six (6) unstained formalin fixed paraffin 
embedded (FFPE) slides. These slides will be obtained prior to cycle 1, prior to cycle 2, and prior 
to cycle 3. 
For both DNA and RNA sequencing we will request five (5) 50-mg fresh frozen tumor samples 
from biopsies done prior to cycles 1, 2, and 3. Total nucleic acids will be purified using the 
AllPrep DNA/RNA kit (Qiagen) or the total nucleic extraction kit (Ambion/Thermo Fisher).  
DNA will be subjected to targeted gene sequencing, whole exome, or whole genome sequencing 
using the Illumina next generation sequencing platform. RNA will be processed for RNA-seq 
with both Illumina Total RNA-seq protocol and SeqLL single molecule digital gene expression.
All slides for RNA-ISH and frozen tumor samples for RNA-seq will be sent to
Ting Laboratory
MGH Cancer Center

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
51
149 13th Street
CNY149 – 614
Charlestown MA 02129
9.2
Functional DNA Damage Response Biomarkers
Complementary to the studies described in Section 9.1, we will use any excess available tumor 
tissues for exploratory functional protein studies as described (Willers 2015). Using established 
protocols and depending on tissue availability we will generate organoid tumor cell lines and/or 
directly use fresh tumor tissue (volume equivalent of at least 1 core biopsy). Research specimens 
will be subjected to radiation, niraparib, or additional agents ex vivo and foci responses of 
proteins involved in the DNA damage response will be analyzed by immunofluorescence 
microscopy or immunohistochemistry. Additional molecular markers will be assessed as needed. 
The analysis is exploratory, seeking to correlate functional DNA damage response markers with 
tumor responses in individual patients. The studies will be mainly performed in the 
Willers Laboratory
MGH Radiation Oncology CNY149-4406
149 13th Street
Charlestown, MA 02129
9.3
 Blood-based Correlative Studies
Peripheral blood will be collected serially or by port draw throughout study treatment as 
specified in the studycalendar. 40mL of blood will be collected at each time point into two 10mL 
Streck cfDNA fixative tubes and two Becton Dickinson Mononuclear Cell Preparation Tubes, 
and tubes will be centrifuged to separate cell pellet from plasma, and each component will be 
aliquoted and frozen for subsequent analysis. 
Blood samples in Streck cfDNA tubes can be shipped at room temperature (within 5 days of 
draw) to:
Corcoran Laboratory
Massachusetts General Hospital Cancer Center
149 13th St, Room 7330
Charlestown, MA 02129
Blood samples in BD Mononuclear Cell Preparation tubes will be sent on the day of draw to:
Ting Lab
Massachusetts General Hospital Cancer Center
Charlestown Navy Yard Building 124- 6-618B
13th Street Building 124
Charlestown, 02129
9.3.1
Serial monitoring of tumor burden and therapeutic resistance by circulating tumor DNA 
analysis
Cell free DNA will be isolated from serial plasma aliquots. PBMCs will be isolated and purified
from the blood cell pellet and frozen separately for immune cell analyses. The T cell TCR locus

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
52
and gene expression profiles from these pellets will be characterized by RNA-seq to study T cell
clonality and functionality over the course of therapy. For each patient one to two specific clonal
mutations identified by exome sequencing of tumor tissue (above) will be used to track
circulating tumor DNA (ctDNA) levels throughout treatment using custom mutation-specific
droplet digital PCR probes as a personalized measure of tumor burden. This method will allow
accurate monitoring of the response of overall tumor burden to treatment and can be correlated
with radiologic endpoints, both as an additional measure of treatment response and as a potential
method to discriminate between “pseudo-progression” and tumor progression. Cell free DNA
isolated from baseline plasma and plasma obtained at progression will also be analyzed by whole
exome sequencing using the Broad Institute blood biopsy platform to identify genetic changes
that have emerged in tumor cells upon development of therapeutic resistance. Therapeutic
resistance is often caused by molecular alterations affecting key target pathways, and these
changes can frequently be detected in ctDNA upon progression. This will serve as an important
discovery effort to identify potential mechanism of acquired resistance to therapy.
9.3.2
Assessment of T-cell Receptor (TCR) repertoire
Peripheral blood mononuclear cells (PBMCs) will be isolated from cell pellets from the serial
peripheral blood draws. The TCR repertoire analysis will be performed using the Broad Institute
sequencing platform. For each patient, the peripheral TCR repertoire will be tracked over the
course of therapy and compared with the intratumoral TCR repertoire.
9.3.3
Potential Risks to Patients
These studies will involve peripheral blood draw only. Peripheral blood draws do involve a
small risk of patient discomfort, bruising, or puncture site infection, but these risks are minimal.
Furthermore, correlative blood draws will be performed at the same time as patients are 
havingroutine clinical blood laboratory assessments during study treatment, and thus will not 
involve any additional peripheral venipuncture.
9.4
Patient Reported Outcomes
The FAACT (Functional Assessment of Anorexia/ Cachexia Treatment) and a condensed version 
of the PRO-CTCAE will be used to assess patient reported outcomes at time of informed 
consent, after completion of each cycle, weekly during radiation therapy and when the patient 
comes off study.
10. STUDY CALENDAR
Baseline evaluations are to be conducted within 28 days prior to study registration unless 
otherwise specified.  Scans and x-rays must be done <4 weeks prior to study registration.  In the 
event that the participant’s condition is deteriorating, laboratory evaluations should be repeated 
within 48 hours prior to initiation of the next cycle of therapy.
Screening laboratory assessments must be done within 8 days prior to study registration.  For 
women of childbearing potential, as defined in the eligibility criteria, a urine or serum HCG 
pregnancy test must be completed within 7 days prior to initiating protocol therapy. If a urine 
pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be 
required. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
53
Assessments must be performed prior to administration of any study agent. Study assessments 
and agents should be administered within + 3 days of the protocol-specified date, unless 
otherwise noted.
Tests and Observations
Baseline
Day 1 
Cycle 1
Niraparib/ 
dostarlima
b
Day 1 
Cycle 2
Niraparib
/dostarli
mab/ 
Radiation
Day 1 
Cycles 3+
Niraparib
/dostarli
mab
First 
follow-
up/off 
treatment 
visit (9)
Subsequent 
Follow-up 
(10)
Informed Consent
X
Demographics and 
Medical History
X
Physical Examination (1,2)
X
X
X
X
X
Vital Signs and ECOG PS 
(2)
X
X
X
X
X
Height, Weight (2, 3)
X
X
X
X
ECHO or MUGA (15)
X
Toxicity Assessment
X
X----------------------------------------------X
Laboratory: 
CBC/platelets/diff (13)
X
X
X
X
X
Serum chemistries (Na, 
K, BUN, Cr, Glucose, 
Calcium, Albumin, 
AST, ALT, Total 
bilirubin, Alk phos, 
CPK, lipase) (14)
X
X
X
X
X
Creatinine clearance 
calculation (Cockroft 
Gault) (16)
X
X
X
X
Thyroid panel (8)
X
X
X
CA19-9 and CEA (4)
X
X
X
X
Pregnancy test (5)
X
X
X
X
Urinalysis 
X
X
X
X
X
Bone Marrow Aspirate 
and Biopsy (12)
X
Research Blood for 
Correlative Studies (6)
X
X
X
X
X
Tumor collection for 
Correlative Studies (11)
X
X
X

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
54
Tests and Observations
Baseline
Day 1 
Cycle 1
Niraparib/ 
dostarlima
b
Day 1 
Cycle 2
Niraparib
/dostarli
mab/ 
Radiation
Day 1 
Cycles 3+
Niraparib
/dostarli
mab
First 
follow-
up/off 
treatment 
visit (9)
Subsequent 
Follow-up 
(10)
Patient Reported 
Outcomes (NCI PRO-
CTCAE and FAACT) (17)
X
X
X
X
X
CT of Chest/ Abdomen/ 
Pelvis (or MRI)
X
X (7)
X
Tumor Measurement
X
X (7)
X
Concomitant Meds
X
X----------------------------------------------X
Survival Status 
X
1)
Physical exam must include a general, basic neurologic assessment
2)
Heart rate and blood pressure monitoring will be required weekly,  in clinic if possible, for the 
first two months of or Niraparib/ Dostarlimab (until C3D15). After the first 2 months of therapy, 
blood pressure and heart rate monitoring must be checked monthly for the first year of treatment. 
For the weekly checks, monitoring at or near home is acceptable.  
3)
Height is only required at baseline. 
4)
Tumor markers will be drawn prior to or at the time of radiological evaluation with routine labs. 
5)
For women of child-bearing potential only (definition of non-childbearing potential in eligibility 
criteria). A serum or urine pregnancy test is required within 7 days of starting protocol therapy, 
every 9 weeks while on treatment, and at least 30 days after last dose of protocol therapy. 
6)
Correlative labs will be drawn at the following time points: Baseline, post-dose 1, pre-radiation, 
pre-cycle 3, and off-treatment. 
7)
Restaging scans (CT or MRI) are due after every two (42) day cycles (12 weeks) of Niraparib/ 
dostarlimab (pre-cycle 5, pre-cycle 7, pre-cycle 9, etc.) while on treatment. 
8)
Blood samples for the thyroid panel (i.e., TSH, T3 or FT3, FT4, or equivalent tests) are to be 
collected during screening, Cycle 2/Day 1, Cycle 4/Day 1, Cycle 5/Day 1, and the start of each 
cycle thereafter through the remainder of the study (blood samples can be collected up to 7 days 
prior to dostarlimab administration). TSH results do not need to be available prior to treatment. 
9)
 The first follow up visit and/or off treatment visit will be at least 30 days from the last dose (+/- 7 
days) or may coincide with the date of discontinuation of treatment (+/- 7 days) if the date of 
discontinuation is greater than 37 days after the last dose. 
10) Patients will either be seen in clinic or called every 12 weeks for the first two years of follow-up 
and then at least every 6 months for years 3-5 and followed for survival status. 
11) Tumor collection for correlative analysis will occur prior to cycle 1, prior to cycle 2, and prior to 
cycle 3 if safely accessible by percutaneous approach. 
12) For any patient diagnosed with MDS/AML while on study, a bone marrow aspirate/biopsy must be 
completed by a local hematologist. Testing completed as part of standard of care is sufficient as 
long as the methods are acceptable to GSK. A copy of the hematologist's report of aspirate/biopsy 
findings including a classification according to WHO criteria and other sample testing results 
related to MDS/AML will be provided to the PI and to GSK.
13) CBC to include absolute neutrophil count, platelets, and hemoglobin.  CBC must be collected on 
Cycle 1 Day 1 and weekly during the first cycle.  Labs completed on Cycle 1 Day 1 should 
re-meet eligibility prior to dosing.  CBC should also be drawn weekly for the first two 
cycles of Niraparib/ Dostarlimab.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
55
14) Treatment may be administered after review of hematology and chemistry laboratory values, 
while CPK result is pending if the patient is asymptomatic. It is preferred that CPK value be 
available prior to dosing, however dosing does not need to be delayed if CPK value is not 
available by time of dosing.
15) Clinically significant abnormalities on ECHO/MUGA will be determined by treating clinician. 
Patients with uncontrolled cardiovascular disease will be excluded per exclusion criteria.
16) Creatinine clearance calculation is not a parameter to receive treatment. Clinically significant 
abnormalities will be determined by treating clinician and managed per SOC.
17) Patient will be asked to complete Patient Reported Outcome Surveys at baseline, the end of each 
cycle, weekly during radiation and at the end of study.
11. MEASUREMENT OF EFFECT
11.1
Antitumor Effect – Solid Tumors
For the purposes of this study, participants should be re-evaluated for response every 12 weeks 
while on treatment.  In addition to a baseline scan, confirmatory scans should also be obtained 4 
weeks following initial documentation of objective response.
Response and progression will be evaluated in this study using the international criteria proposed 
by BOTH the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) 
(Eisenhauer 2009) as well as the Immune-related Response Evaluation Criteria in Solid Tumors 
(irRECIST) (Wolchok 2009) as administered by the Dana-Farber/ Harvard Cancer Center Tumor 
Imaging Metrics Core.  
11.1.1 Response Review
Central review of baseline and restaging scans will be performed by the Dana-Farber Harvard 
Cancer Center Tumor Imaging Metrics Core. 
12. DATA REPORTING / REGULATORY REQUIREMENTS
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0.
12.1
Data Reporting
12.1.1 Method
The Office of Data Quality (ODQ) will collect, manage, and perform quality checks on the data 
for this study.
12.1.2 Responsibility for Data Submission
Investigative sites within DF/HCC or DF/PCC are responsible for submitting data and/or data 
forms to the Office of Data Quality (ODQ) in accordance with DF/HCC policies.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
56
12.2
Data Safety Monitoring
The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor toxicity 
and accrual data from this study. The committee is composed of medical oncologists, research 
nurses, pharmacists and biostatisticians with direct experience in cancer clinical research.  
Information that raises any questions about participant safety will be addressed with the Overall 
PI and study team.
The DSMC will review each protocol up to four times a year with the frequency determined by 
the outcome of previous reviews. Information to be provided to the committee may include: up-
to-date participant accrual; current dose level information; DLT information; all grade 2 or 
higher unexpected adverse events that have been reported; summary of all deaths occurring 
within 30 days of intervention for Phase I or II protocols; for gene therapy protocols, summary of 
all deaths while being treated and during active follow-up; any response information; audit 
results, and a summary provided by the study team. Other information (e.g. scans, laboratory 
values) will be provided upon request. 
13. STATISTICAL CONSIDERATIONS
The primary endpoint is disease control defined as CR, PR or SD for at least 3 months based on 
RECIST 1.1 (section 11.1). A 20% rate of disease control rate is specified under the alternative 
hypothesis as the minimum level of promising efficacy, while a 5% rate is specified as an upper 
bound under the null hypothesis of minimal or no activity. The null and alternative hypotheses 
reflect the virtually lack of therapeutic options for metastatic pancreatic cancer and the very poor 
prognosis overall.
13.1
Study Design
A two-stage design will be used to evaluate the efficacy of niraparib and  dostarlimab combined 
with radiation. Initially, 15 patients will be enrolled during the first stage of accrual. If none of 
them were to achieve disease control, the protocol will be terminated with no further accrual. 
The probability of stopping early is 46% if the underlying rate of disease control were truly 5% 
in the patient population. If at least 1 of the first 15 patients were to achieve disease control, the 
protocol will proceed to enroll a total of 25 patients. Niraparib and  dostarlimab combined with 
radiation will be considered to have promising activity in metastatic pancreatic cancer if at least 
3 patients overall were to achieve disease control. The two-stage design provides 89% power to 
accept the treatment combination is associated with a 20% rate of disease control. On the other 
hand, the probability of a type 1 error is only 12% if the underlying rate of disease control were 
truly only 5%. The two-stage design is optimal as well as minimax based on the Simon criteria in 
meeting a target alpha level of 0.15.    
13.2
Sample Size, Accrual Rate and Study Duration
The accrual duration is projected to be about 2 years to enroll a final total of 25 patients with 
metastatic pancreatic cancer. Each patient will be followed long-term up to 5 years for survival 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
57
according to the study calendar (section 10).
13.3
Interim Monitoring Plan
The two-stage design (section 13.1) implements an early stopping rule after the initial 15 patients 
have treated during the first stage and evaluated for disease response.
13.4
Analysis of Primary Endpoint
The disease control rate will be reported as a summary measure of disease response evaluated by 
RECIST 1.1 (section 11.1) and estimated with the 95% confidence interval based on the exact 
binomial distribution.
13.5
Analysis of Secondary and Exploratory Endpoints

The rate of disease control evaluated by irRECIST will be estimated with the 95% 
confidence interval based on the exact binomial distribution.

Progression-free survival is defined as the duration from the first day of protocol 
treatment to the earlier date of disease progression or death due to any cause. PFS time 
will be censored at the date of last follow-up for surviving patients with disease control. 
The PFS rate will be estimated by the Kaplan-Meier method with 95% confidence 
intervals based on the complementary log-log transformation.

Overall survival is defined as the duration from the first day of protocol treatment to the 
date of death due to any cause and will be censored at the date of last follow-up for 
patients still alive. The OS rate will be estimated by the Kaplan-Meier method with 95% 
confidence intervals based on the complementary log-log transformation.

Toxicity associated with the combination of niraparib and  dostarlimab with radiation will 
be summarized by category and grade.

Serial tumor biopsies will be obtained at baseline in conjunction with fiducial placement, 
after cycle 1 of niraparib and  dostarlimab and after cycle 2 following the addition of 
radiation. Tissue will be analyzed for repeat RNA expression and immune infiltrates 
(section 9.1) by RNA-ISH and RNAseq assays. The immune markers will generally be 
analyzed at paired timepoints in order to isolate changes due to anti-PD1 and PARP 
inhibition alone and cooperative effects of combined inhibition and radiation. Standard 
parametric and non-parametric methods for analysis of paired data will be used, applying 
appropriate transformations as needed. As tumor biopsies may not be obtained on all 
patients and/or all timepoints, the marker analyses will be exploratory.

Peripheral blood will be collected at the same timepoints as tumor biopsy as well as at 
off-treatment due to disease progression for serial analyses of ctDNA (9.3.1) and T-cell 
receptor (TCR) repertoire (9.3.2). ctDNA levels of one or two specific clonal mutations 
will be used as a personalized measure of overall tumor burden and correlated with 
radiologic endpoints. ctDNA at baseline and progression will be compared to identify 
genomic changes emerging at development of therapeutic resistance. Peripheral and 
intra-tumoral TCR repertoires will be compared within patients. ctDNA and TCR data 
will be analyzed primarily using graphical and descriptive methods to identify potential 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
58
trends and associations. Analyses will be exploratory and hypothesis-generating due to 
the optional assessments.

The FAACT (Functional Assessment of Anorexia/ Cachexia Treatment) and a condensed 
version of the PRO-CTCAE will be used to assess patient reported outcomes at time of 
informed consent, after completion of each cycle, weekly during radiation therapy and 
when the patient comes off study. Analyses will be exploratory. 
13.6
Reporting and Exclusions
13.6.1 Evaluation of Toxicity
All enrolled patients will be evaluable for toxicity starting from their first dose of protocol 
treatment.
13.6.2 Evaluation of the Primary Efficacy Endpoint
All eligible patients will be assessed for disease control and analyzed for efficacy, including 
those unevaluable according to RECIST 1.1 or irRECIST due to early discontinuation of 
protocol treatment for any reason or early death due to toxicity or disease. 
14. PUBLICATION PLAN
The results should be made public within 24 months of reaching the end of the study. The end of 
the study is the time point at which the last data items are to be reported, or after the outcome 
data are sufficiently mature for analysis, as defined in the section on Sample Size, Accrual Rate 
and Study Duration. If a report is planned to be published in a peer-reviewed journal, then that 
initial release may be an abstract that meets the requirements of the International Committee of 
Medical Journal Editors. A full report of the outcomes should be made public no later than three 
(3) years after the end of the study. 

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
59
REFERENCES
Berry DL. Patient-reported symptoms and quality of life integrated into clinical cancer care. 
Seminars in oncology nursing 2011;27:203-10.
Bersani F, Lee E, Kharchenko PV, et al., Pericentromeric satellite repeat expansions through 
RNA-derived DNA intermediates in cancer. Proc Natl Acad Sci U S A, (2015); 112(49): 15148-
53.
Brown JS, Sundar R, Lopez J, Combining DNA damaging therapeutics with immunotherapy: 
more haste, less speed. Br J Cancer, 2018. 118: 312-324.
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic 
pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817–1825
Curtin, N.J., DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer, 
2012. 12(12): p. 801-17.
Dholakia, A.S., et al., Mapping patterns of local recurrence after pancreaticoduodenectomy for 
pancreatic adenocarcinoma; a new approach to adjuvant radiation field design. Int J Radiat Oncol 
Biol Phys, 2013. 87(5): 1007-1015.
Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of 
targeted therapies? Journal of the National Cancer Institute 2008;100:240-2.
Eisenhauer EA, Therasse P, Bogaerts J, et. al., New response evaluation criteria in solid tumours; 
revised RECIST guideline (version 1.1) Eur J Cancer, (2009); 45(2): 228-247.
Flynn RL, Cox KE, Jeitany M, et. al., Alternative lengthening of telomeres renders cancer cells 
hypersensitive to ATR inhibitors. Science, (2015); 347(6219): 273-7.
Greenbaum BD, Cocco S, Levine AJ, and Monasson R, Quantitative theory of entropic forces 
acting on constrained nucleotide sequences applied to viruses. Proc Natl Acad Sci U S A, (2014); 
111(13): 5054-9.
Greenbaum BD, Levine AJ, Bhanot G, and Rabadan R, Patterns of evolution and host gene 
mimicry in influenza and other RNA viruses. PLoS Pathog, (2008); 4(6): e1000079.
Greenbaum BD, Rabadan R, and Levine AJ, Patterns of oligonucleotide sequences in viral and 
host cell RNA identify mediators of the host innate immune system. PLoS One, (2009); 4(6): 
e5969.
Holter, S., et al., Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients with 
Pancreatic Adenocarcinoma. J Clin Oncol, 2015. 33(28): p. 3124-9.
Huang, J., et al., The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-
/-) murine model of ovarian cancer. Biochem Biophys Res Commun, 2015. 463(4): p. 551-6.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
60
Jones P, et al., Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of 
Tumors with Defective Homologous Recombination. J Med Chem. 2015 Apr 23;58(8):3302- 
3314.
Jurka J, Kapitonov VV, Pavlicek A, et. al., Repbase Update, a database of eukaryotic repetitive 
elements. Cytogenet Genome Res, (2005); 110(1-4): 462-7.
Matulonis, U.A. and B.J. Monk, PARP inhibitor and chemotherapy combination trials for the 
treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol, 
2017. 28(3): p. 443-447.
Matulonis, U.A., et al., Olaparib monotherapy in patients with advanced relapsed ovarian cancer 
and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann 
Oncol, 2016. 27(6): p. 1013-9.
Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. Simultaneous care: a model 
approach to the perceived conflict between investigational therapy and palliative care. Journal of 
pain and symptom management 2004;28:548-56.
Oberguggenberger A, Hubalek M, Sztankay M, et al. Is the toxicity of adjuvant aromatase 
inhibitor therapy underestimated? Complementary information from patient-reported outcomes 
(PROs). Breast cancer research and treatment 2011;128:553-61.
Shirabe K, Motomura T, Muto J, et al. Tumor-infiltrating lymphocytes and hepatocellular 
carcinoma: pathology and clinical management. International journal of clinical oncology. 
2010;15(6):552-558.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 
2017; 67: 7-30
Talmadge JE. Immune cell infiltration of primary and metastatic lesions: mechanisms and 
clinical impact. Seminars in cancer biology. 2011;21(2):131-138.
Tanne A, Muniz LR, Puzio-Kuter A, et. al., Distinguishing the immunostimulatory properties of 
noncoding RNAs expressed in cancer cells. Proc Natl Acad Sci U S A, (2015); 112(49): 15154-9.
Ting DT, Lipson D, Paul S, et. al., Aberrant overexpression of satellite repeats in pancreatic and 
other epithelial cancers. Science, (2011); 331(6017): 593-6.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-
paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703
Waddell, N., et al., Whole genomes redefine the mutational landscape of pancreatic cancer. 
Nature, 2015. 518(7540): p. 495-501.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
61
Willers H, Gheorghiu L, Liu Q, et. al., DNA damage response assessments in human tumor 
samples provide functional biomarkers of radiosensitivity. Semin Radiat Oncol, (2015); 25(4): 
237-250. 
Wolchok JD, Hoos A, O’Day S, et. al., Guidelines for the evaluation of immune therapy activity 
in solid tumors: Immune-related Response Criteria. Clin Cancer Res, 2009; 15(23): 7412-7420.
Zhu Q, Pao GM, Huynh AM, et. al., BRCA1 tumour suppression occurs via heterochromatin-
mediated silencing. Nature, (2011); 477(7363): 179-84.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
62
APPENDIX A
PERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale
Karnofsky Performance Scale
Grade
Descriptions
Percent
Description
100
Normal, no complaints, no evidence 
of disease.
0
Normal activity.  Fully active, able 
to carry on all pre-disease 
performance without restriction.
90
Able to carry on normal activity; 
minor signs or symptoms of disease.
80
Normal activity with effort; some 
signs or symptoms of disease.
1
Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).
70
Cares for self, unable to carry on 
normal activity or to do active work.
60
Requires occasional assistance, but 
is able to care for most of his/her 
needs.
2
In bed <50% of the time.  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.
50
Requires considerable assistance and 
frequent medical care.
40
Disabled, requires special care and 
assistance.
3
In bed >50% of the time.  Capable 
of only limited self-care, confined 
to bed or chair more than 50% of 
waking hours.
30
Severely disabled, hospitalization 
indicated.  Death not imminent.
20
Very sick, hospitalization indicated. 
Death not imminent.
4
100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair.
10
Moribund, fatal processes 
progressing rapidly.
5
Dead.
0
Dead.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
63
APPENDIX B
NIRAPARIB DRUG DIARY
1.1.1
Participant Name: __________________________
Your Doctor_____________________ Phone___________________
Your Nurse______________________ Phone___________________
Dosing Instructions for Niraparib:
Your dose of Niraparib is ______ mg made up of ______ - ______ mg capsules. 

You should take your dose of niraparib once daily at approximately the same 
time.

Please wash your hands after handling niraparib. If a caregiver is giving 
niraparib to you, they should wear disposable gloves. Extra care should be 
used if powder is observed to avoid contact with your skin or eyes. If 
contract does occur, flush eyes or skin with water. 

If you miss your dose of niraparib by less than 12 hours from your normal 
dosing time, the dose can be made up. If you missed your dose by more than 
12 hours, wait until the next scheduled dosing time and take the next 
scheduled dose.

If you vomit your dose of niraparib, do not re-dose. Resume dosing at your 
next scheduled dose.

Capsules should be taken whole and not crushed, chewed, opened or 
dissolved in water.

Niraparib can be taken with or without food and water.

Store niraparib at room temperature (59°F-86°F (15°C-30°C)).

Please bring this diary along with any empty or partially empty bottles to 
each study visit.
1.1.2
Study Participant Self-Administration Drug Diary
DFCI Study Number: 19-538

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
64
1.1.3
DOSING LOG: Cycle ____
Dosing Log Instructions
Make sure to indicate the date, time, amount taken and any comments immediately following each dose.
Bring your study drug containing all remaining medication, including empty bottles, to each visit.
Once complete, provide this signed or initialed and dated dosing log to your study doctor or nurse.
Day 
Date
Time of Dose
Number of 
Niraparib 
Capsules 
Taken
Comments
If dose was vomited, missed or skipped, 
indicate reason below.
1
□am/□pm
2
□am/□pm
3
□am/□pm
4
□am/□pm
5
□am/□pm
6
□am/□pm
7
□am/□pm
8
□am/□pm
9
□am/□pm
10
□am/□pm
11
□am/□pm
12
□am/□pm
13
□am/□pm
14
□am/□pm
15
□am/□pm
16
□am/□pm
17
□am/□pm
18
□am/□pm
19
□am/□pm
20
□am/□pm
21
□am/□pm
Participant Signature or Initials
Date

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
65
APPENDIX C
NCI PRO-CTCAE Survey
NCI PRO-CTCAE™ ITEMS
Item Library Version 1.0
English
Form created on 11 March 2020
As individuals go through treatment for their cancer they sometimes experience
different symptoms and side effects. For each question, please check or mark an
in the one box that best describes your experiences over the past 7 days…
1. In the last 7 days, did you have any RASH?
○ Yes ○ No
2. In the last 7 days, what was the SEVERITY of your DRY SKIN at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
3. In the last 7 days, did you have any HAIR LOSS?
○ Not at all ○ A little bit ○ Somewhat ○ Quite a bit ○ Very much
4. In the last 7 days, what was the SEVERITY of your ITCHY SKIN at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
5. In the last 7 days, did you have any HIVES (ITCHY RED BUMPS ON THE
SKIN)?
○ Yes ○ No
6. In the last 7 days, what was the SEVERITY of your SKIN BURNS FROM RADIATION at 
their WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe ○ Not applicable
7. In the last 7 days, did you have any UNUSUAL DARKENING OF THE SKIN?
○ Yes ○ No
The PRO-CTCAE™ items and information herein were developed by the NATIONAL CANCER INSTITUTE at the NATIONAL
INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE™ is subject to NCI's Terms of Use.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
66
NCI PRO-CTCAE™ ITEMS
Item Library Version 1.0
English
Form created on 11 March 2020
Do you have any other symptoms that you wish to report?
○ Yes ○ No
Please list any other symptoms:
1. In the last 7 days, what was the SEVERITY of this symptom at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
2. In the last 7 days, what was the SEVERITY of this symptom at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
3. In the last 7 days, what was the SEVERITY of this symptom at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
4. In the last 7 days, what was the SEVERITY of this symptom at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
5. In the last 7 days, what was the SEVERITY of this symptom at its WORST?
○ None ○ Mild ○ Moderate ○ Severe ○ Very severe
Powered by TCPDF (www.tcpdf.org)
The PRO-CTCAE™ items and information herein were developed by the NATIONAL CANCER INSTITUTE at the NATIONAL
INSTITUTES OF HEALTH, in Bethesda, Maryland, U.S.A. Use of the PRO-CTCAE™ is subject to NCI's Terms of Use.

DF/HCC Protocol #: 19-538
Protocol Version Date: January 21, 2021
67